hp09-2016sd: the supply and delivery of solid dosage … · [email protected] ranbaxy...
TRANSCRIPT
HP09-2016SD: THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 AUGUST 2016 TO 31 JULY 2018
2
1. IMPORTANT GENERAL INFORMATION:
1.1 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
1.2 All prices are inclusive of 14 % VAT.
1.3 All prices are on a delivered basis. 1.4 Where 28-day packs are specified and 30-day packs awarded, this is not indicated
as a deviation from specification, but indicated in the unit column. This applies to the following pack sizes:
28 vs 30 56 vs 60
84 vs 90 100 vs 112
1.5 Where an item has been split between more than one supplier, a single NSN is
used, even if the awarded sizes differ as above.
1.6 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.
2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL
Supplier Name Supplier
Code Postal Address Contact Detail:
Tel Number ---------------------Fax Number
Contact Person ---------------------- E-mail Address
Abbott Laboratories (Pty) Ltd
V2150 P O Box 7208 WELTEVREDEN PARK 1715
(011) 858-2250 (086) 231-2329
Neren Lorrick [email protected]
Accord Healthcare (Pty) Ltd
V2MB8 Postnet 182 Private Bag X51 RIVONIA 2128
(011) 234-5703 (011) 234-5700
Reshlan Nagoor [email protected]
Adcock Ingram Critical Care (Pty) Ltd
V4222 P O Box 6888 JOHANNESBURG 2000
(011) 494-8000 (086) 553-0460
Tahera Munshi [email protected]
Adcock Ingram Healthcare (Pty) Ltd
V2272 Private Bag X69 BRYANSTON 2021
(011) 635-0671 (086) 553-0671
Louis Fourie [email protected]
Akacia Healthcare (Pty) Ltd
V0DM6 P O Box 194 ISANDO 1600
(087) 357-6077 (086) 618-8442
Sue Venter [email protected]
AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Private Bag X23 BRYANSTON 2021
(011) 797-6166 (086) 676-5948
Singatwa Mnqandi [email protected]
Austell Laboratories (Pty) Ltd
V1A10 P O Box 1110 CROWN MINES 2025
(011) 611-1400 (011) 839-0401
Younus Karolia [email protected]
Bayer (Pty) Ltd V6390 P O Box 143 ISANDO1600
(011) 921-5279 (011) 921-5272
Magda Noack [email protected]
HP09-2016SD: THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 AUGUST 2016 TO 31 JULY 2018
3
Supplier Name Supplier Code
Postal Address Contact Detail:
Tel Number ---------------------Fax Number
Contact Person ---------------------- E-mail Address
Biotech Laboratories (Pty) Ltd
VUV35 Suite 150 Private Bag X65 HALFWAY HOUSE 1685
(011) 848-3050 (011) 848-3065
Duduzile Mofolo [email protected]
Cipla Medpro South Africa (Pty) Ltd
VXZ32 P O Box 32003 MOBENI 4060
(011) 315-9150 (021) 914-0531
Willem Maritz [email protected]
Dezzo Trading 392 (Pty) Ltd
V05Y6 P O Box 725 LAWLEY 1824
(011) 857-2090 (086) 265-2233
Omar Matthews [email protected]
Dr Reddy's Laboratories (Pty) Ltd
V1A08 P O Box 784746 SANDTON 2146
(011) 324-2112 (011) 388-1262
Lorraine Keyser [email protected]
Equity Pharmaceuticals (Pty) Ltd
V1QZ3 P O Box 60964 PIERRE VAN RYNEVELD 0045
(012) 345-1747 (012) 345-1412
Benjamin Miny [email protected]
Ferring Pharmaceutical (Pty) Ltd
VXY92 P O Box 14358 CLUBVIEW 0014
(012) 345-6358 (012) 345-1156
Mercia van Zyl [email protected]
Gulf Drug Company (Pty) Ltd
VTS03 P O Box 1523 DURBAN 4000
(031) 538-8700 (031) 502-2379
Kevin Moonsamy [email protected]
Innovata Pharmaceuticals (Pty) Ltd
VBBL4 P O Box 777 KELVIN 2054
(086) 999-0912 (086) 585-5129
Imraan Suliman [email protected]
Litha Pharma (Pty) Ltd
VGS73 P O Box 83 MIDRAND 1685
(087) 742-1691 (087) 742-1666
Barry Budler [email protected]
Meda Pharma South Africa (Pty) Ltd
V2ZD6 Post Net Suite #166 Private Bag X9976 SANDTON 2196
(011) 302-1260 (011) 784-1428
Riaan Botes [email protected]
Medicine Developers International (Pty) Ltd
V3LJ8 P O Box 725 LAWLEY 1824
(011) 857-2090 (086) 265-2233
Omar Matthews [email protected]
Merck (Pty) Ltd V3018 P O Box 1998 HALFWAY HOUSE 1685
(011) 957-2989 (086) 652-8217
Bev Brits [email protected]
Mirren (Pty) Ltd V7149 P O Box 12348 BENORYN 1504
(011) 425-4026 (011) 425-0808
Maureen Kruger [email protected]
Mylan (Pty) Ltd V3PS6 Postnet Suite 23 Private Bag X10010 EDENVALE 1610
(011) 451-1300 (011) 451-1400
Nathi Mthethwa [email protected]
Novartis South Africa (Pty) Ltd
VBVW2 P O Box 12257 VORNA VALLEY 1686
(011) 347-6846 (011) 929-2479
Darisha Singh [email protected]
HP09-2016SD: THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 AUGUST 2016 TO 31 JULY 2018
4
Supplier Name Supplier Code
Postal Address Contact Detail:
Tel Number ---------------------Fax Number
Contact Person ---------------------- E-mail Address
Pfizer Laboratories (Pty) Ltd
V2189 P O Box 783720 SANDTON 2146
(011) 320-6000 (011) 895-1491
Themba Mnguni [email protected]
Pharmacare Limited V2205 P O Box 1593 GALLO MANOR 2052
(011) 239-6243 (086) 574-3175
Jaco De Wet [email protected]
Pharmaceutical Contractors (Pty) Ltd
VCJF7 P O Box 427 ISANDO 1600
(011) 974-1631 (011) 974-7520
Claudio Manoel Martins [email protected]
Pharmachem Laboratories (Pty) Ltd
V3LA8 Private Bag X12 PRETORIA WEST 0117
(012) 749-4800 (086) 575-4622
Bilaal Jeewa [email protected]
Pharmaco Distribution (Pty) Ltd
VBVW1 P O Box 786522 SANDTON 2146
(011) 784-0077 (011) 784-6994
Jan van den Berg [email protected]
Portfolio Pharmaceuticals (Pty) Ltd
VWB81 P O Box 591292 KENGRAY 2100
(011) 334-5530 (011) 334-9521
Jenny Holland [email protected]
Ranbaxy Pharmaceuticals (Pty) Ltd
V4728 P O Box 43486 INDUSTRIA 2042
(012) 643-2000 (086) 662-7031
Deepak M Sewnarain [email protected]
Ranbaxy South Africa (Pty) Ltd
VVZ04 P O Box 10458 CENTURION 0046
(012) 643-2000 (086) 662 7031
Deepakh M Sewnarain [email protected]
Resmed Healthcare CC
VCEJ2 P O Box 65409 RESERVOIR HILLS 4090
(031) 577-7258 (031) 577-7182
Laljith Sunker Singh [email protected]
Roche Products (Pty) Ltd
V2177 P O Box 55922 NORTHLANDS 2196
(011) 502-5000 (011) 268-5738
Mongezi Sokanyile [email protected]
Sandoz SA (Pty) Ltd VVZ69 P O Box 154 ISANDO 1600
(011) 929-9002 (011) 394-5935
Renee Moodley [email protected]
Sanofi-Aventis South Africa (Pty) Ltd
V2160 Private Bag X207 MIDRAND 1683
(011) 256-3750 (086) 646 4833
Gavin Bauer [email protected]
Zentiva South Africa (Pty) Ltd
VBVW0 Private Bag X207 MIDRAND 1683
(011) 256-3750 (086) 646-4833
Gavin Bauer [email protected]
Zinplex Marketing CC
V22Z6 P O Box 678 GARSFONTEIN 0042
(086) 111-9462 (012) 803-9283
Hermanus J H Fourie [email protected]
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
1 Acetazolamide 250mg tablet, 28 tablets
124 783 Adcock Ingram Healthcare (Pty) Ltd
V2272 Azomid R 19.6247 30 tablets 14 1 shipper (72 packs)
95.00 189752737 CO
2 Acetazolamide 250mg tablet, 100 tablets
111 108 Adcock Ingram Healthcare (Pty) Ltd
V2272 Azomid R 46.4195 100 tablets 14 1 shipper (50 packs)
95.00 189710142 CO
4 Acetylcysteine 200mg tablet, 25 tablets
8 620 Sandoz SA (Pty) Ltd VVZ69 ACC 200mg 25 EFF tabs
R 46.0300 25 tablets 14 100 94.00 181896924 EA
5 Acitretin 10mg capsule, 28 capsules
5 654 Akacia Healthcare (Pty) Ltd
V0DM6 Neotigason 10mg R 603.6900 30 capsules 14 1 90.00 180179717 CO
6 Acitretin 25mg capsule, 28 capsules
10 143 Akacia Healthcare (Pty) Ltd
V0DM6 Neotigason 25mg R 1 275.3100 30 capsules 14 1 90.00 180179725 CO
7 Alendronic acid 10mg tablet,28 tablets
61 378 Accord Healthcare (Pty) Ltd
V2MB8 Ostena 10mg R 20.5200 28 tablets 14 20 94.00 181918030 CO
8 Alfacalcidol 0,25mcg capsule, 28 capsules
81 265 Adcock Ingram Critical Care (Pty) Ltd
V4222 One-Alpha Capsules 0.25ug
R 168.5718 30 capsules 14 1 box 95.00 189712166 CO
9 Alfacalcidol 1mcg capsule, 28 capsules
37 188 Adcock Ingram Critical Care (Pty) Ltd
V4222 One-Alpha Capsules 1ug
R 527.9340 30 capsules 14 1 box 95.00 189714139 CO
10 Allopurinol 100mg tablet, 28 tablets
282 985 Austell Laboratories (Pty) Ltd
V1A10 Austell Allopurinol 100
R 8.0290 28 tablets 14 600 99.00 181923347 CO
11 Allopurinol 100mg tablet, 56 tablets
129 254 Austell Laboratories (Pty) Ltd
V1A10 Austell Allopurinol 100
R 15.0200 56 tablets 14 300 99.00 181934797 CO
12 Allopurinol 100mg tablet, 100 tablets
79 031 Austell Laboratories (Pty) Ltd
V1A10 Austell Allopurinol 100
R 33.1850 100 tablets 14 160 99.00 180105006 CO
13 Allopurinol tablet 100mg, 500 tablets
9 712 Pharmacare Limited V2205 Puricos 100mg Tabs 500
R 262.4964 500 tablets 14 5 95.00 189710123 CO
14 Allopurinol 300mg tablet, 28 tablets
976 484 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Allopurinol 300mg
R 14.0585 30 tablets 14 1 shipper (72 Packs)
95.00 180339396 PG
15 Alprazolam 0,5mg tablet, 30 tablets
5 301 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Zopax 0.5 R 9.5300 30 tablets 14 88 99.00 189714591 CO
16 Amantadine 100mg capsule, 20 capsules
26 446 Novartis South Africa (Pty) Ltd
VBVW2 Symmetrel 100mg capsules
R 105.5900 20 capsules 14 1 93.00 189710390 CO
17 Amiodarone 200mg tablet, 28 tablets
44 360 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Amiodarone 200mg Tablets 30's
R 27.5000 30 tablets 14 20 98.00 189710641 CO
18 Amisulpride 50mg tablet, 28 tablets
44 217 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Solian 50mg R 125.8200 30 tablets 14 10 94.00 181807811 CO
19 Amisulpride 200mg tablet, 28 tablets
173 929 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Solian 200mg R 279.2000 30 tablets 14 10 94.00 181807812 CO
Page 1 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
20 Amitriptyline 10mg tablet, 28 tablets
1 284 697 Pharmacare Limited V2205 Trepiline 10mg Tabs 28
R 7.2390 28 tablets 14 140 95.00 180339402 PG
21 Amitriptyline 10mg tablet, 100 tablets
136 000 Pharmacare Limited V2205 Trepiline 10mg Tabs 100
R 25.5702 100 tablets 14 40 95.00 189710133 CO
22 Amitriptyline 25mg tablet, 28 tablets
4 032 855 Pharmacare Limited V2205 Trepiline 25mg Tabs 28
R 4.4000 28 tablets 14 100 95.00 189711829 CO
23 Amitriptyline 25mg tablet, 56 tablets
773 640 Pharmacare Limited V2205 Trepiline 25mg Tabs 56
R 7.4000 56 tablets 14 100 95.00 189711830 CO
24 Amitriptyline 25mg tablet, 84 tablets
370 555 Pharmacare Limited V2205 Trepiline 25mg Tabs 84
R 11.1600 84 tablets 14 60 95.00 189711831 CO
25 Amitriptyline 25mg tablet, 100 tablets
134 635 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Amitriptyline 25
R 15.1100 100 tablets 14 240 98.00 189760812 BT
26 Amitriptyline 25mg tablet, 168 tablets
52 480 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Amitriptyline 25
R 22.4000 168 tablets 14 120 98.00 181917346 CO
27 Amitriptyline 25mg tablet, 500 tablets
8 850 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Amitriptyline 25
R 49.0200 500 tablets 14 50 98.00 189710122 CO
28 Amlodipine 5mg tablet, 28 tablets
11 747 484 37% Austell Laboratories (Pty) Ltd
V1A10 Austell Amlodipine 5mg
R 3.1920 28 tablets 14 600 95.73 181936075 CO
28 Amlodipine 5mg tablet, 28 tablets
11 112 485 35% Dezzo Trading 392 (Pty) Ltd
V05Y6 Indo Amlodopine - 5
R 3.0800 30 tablets 14 500 95.00 181936075 CO
28 Amlodipine 5mg tablet, 28 tablets
8 889 988 28% Cipla Medpro South Africa (Pty) Ltd
VXZ32 Ciplavasc 5 R 3.3300 28 tablets 14 660 91.69 181936075 CO
29 Amlodipine 10mg tablet, 28 tablets
5 529 726 70% Accord Healthcare (Pty) Ltd
V2MB8 Amtas 10mg R 4.0500 30 tablets 14 240 94.00 181936074 CO
29 Amlodipine 10mg tablet, 28 tablets
2 369 883 30% Austell Laboratories (Pty) Ltd
V1A10 Austell Amlodipine 10mg
R 4.6510 28 tablets 14 600 85.64 181936074 CO
34 Aspirin 100mg tablet, 28 tablets
900 000 Bayer (Pty) Ltd V6390 Bayer Aspirin Cardio 100
R 11.5700 30 tablets 14 1 x 30 91.00 181837065 CO
35 Aspirin 300mg soluble scored tablet, 14 tablets
31 550 631 Resmed Healthcare CC VCEJ2 Soluspirin 14's R 5.6886 14 tablets 14 500 x 14's 100.00 189753742 PG
36 Aspirin 300mg soluble scored tablet, 96 tablets
291 850 Resmed Healthcare CC VCEJ2 Soluspirin 96's R 38.7942 96 tablets 14 50 x 96's 100.00 189714405 CO
37 Atenolol 25mg tablet, 28 tablets
17 250 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Tenormin 25 R 25.3900 30 tablets 10 10 95.00 180071921 CO
Page 2 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
38 Atenolol 50mg tablet, 28 tablets
7 604 848 70% Biotech Laboratories (Pty) Ltd
VUV35 Bio-Atenolol 50 Tablets 30's
R 2.7000 30 tablets 14 600 98.00 180339413 PG
38 Atenolol 50mg tablet, 28 tablets
39 Atenolol 100mg tablet, 28 tablets
1 496 000 Austell Laboratories (Pty) Ltd
V1A10 Tenopress 100mg Tablets
R 4.2980 28 tablets 14 480 99.00 180192290 PG
40 Atorvastatin 10mg tablet, 28 tablets
325 352 Mylan (Pty) Ltd V3PS6 Vastor 10mg R 11.1000 28 tablets 14 10 98.00 180142176 CO
41 Atorvastatin 20mg tablet, 30 tablets
769 037 Mylan (Pty) Ltd V3PS6 Vastor 20mg R 17.6600 30 tablets 14 10 98.00 181798133 CO
42 Atorvastatin 40mg tablet, 30 tablets
67 623 Mylan (Pty) Ltd V3PS6 Vastor 40mg R 29.2900 30 tablets 14 10 98.00 181859938 CO
43 Baclofen 10mg tablet, 30 tablets
730 018 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Baclofen 10 Tabs 30
R 17.0000 30 tablets 14 20 98.00 189710127 CO
44 Baclofen 25mg tablet, 30 tablets
29 210 Novartis South Africa (Pty) Ltd
VBVW2 Lioresal 25mg tablets
R 44.6300 30 tablets 14 1 93.00 189710126 CO
47 Bezafibrate 400mg tablet, 28 tablets
149 453 Sandoz SA (Pty) Ltd VVZ69 Bezafibrate 400mg 30 Tab
R 56.7600 30 tablets 14 50 94.00 180000649 CO
48 Biperiden 2mg tablet, 28 tablets
71 510 Pharmaco Ditribution (Pty) Ltd
VBVW1 Akineton R 23.2900 28 tablets 14 10 92.00 181934910 CO
49 Biperiden 2mg tablet, 56 tablets
59 200 Pharmaco Ditribution (Pty) Ltd
VBVW1 Akineton R 46.4800 56 tablets 14 10 92.00 180339393 PG
50 Biperiden 2mg tablet, 84 tablets
10 900 Pharmaco Ditribution (Pty) Ltd
VBVW1 Akineton R 69.7200 84 tablets 14 10 92.00 181934911 CO
54 Buspirone 10mg tablet, 56 tablets
2 652 Pharmacare Limited V2205 Pasrin-10 10mg Tabs 60
R 125.4000 60 tablets 14 10 95.00 189711839 CO
55 Cabergoline 0,5mg tablet, 4 tablets
15 967 Pfizer Laboratories (Pty) Ltd
V2189 Dostinex 0.5mg TAB, 4's
R 195.4400 4 tablets 14 1 93.00 180348494 CO
TO FOLLOW
Page 3 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
56 Calciferol 50 000 IU tablet, 100 tablets
23 193 Pharmacare Limited V2205 Lennon Calciferol 50 000 IU Tabs 100
R 198.4398 100 tablets 14 5 95.00 189759820 CO
57 Calcitriol 0,25mcg capsule, 30 capsules
10 756 Roche Products (Pty) Ltd
V2177 Rocaltrol 0,25mcg R 131.7200 30 capsules 14 1 pack 93.00 189710186 CO
58 Calcium carbonate 420mg equivalent to elemental calcium 168mg. Glycine 180mg chewable tablet, 168 tablets
1 501 328 Pharmaceutical Contractors (Pty) Ltd
VCJF7 PC Glycal Chewable 168's
R 7.8000 168 tablets 28 300 91.00 181860981 PG
59 Calcium, soluble tablet equivalent to elemental calcium 500mg,10 tabletsMCC registered required
7 186 812 70% Pharmaceutical Contractors (Pty) Ltd
VCJF7 PC Calcium 500 10's
R 5.8000 10 tablets 28 600 91.00 180964704 CO
59 Calcium, soluble tablet equivalent to elemental calcium 500mg,10 tabletsMCC registered required
3 080 062 30% Accord Healthcare (Pty) Ltd
V2MB8 Calcium Fizzy R 6.4400 10 tablets 14 50 units 84.07 180964704 CO
60 Calcium, soluble tablet carbonate equivalent to elemental calcium 500mg tablet, 30 tabletsMCC registered required
3 500 000 Zinplex Marketing CC V22Z6 Zinplex Calcium 500mg Dispersible Tablets
R 10.4400 30 tablets 14 100 units 90.00 181917243 CO
62 Captopril 25mg tablet, 60 tablets
42 967 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Captopril 25 Tablets 60's
R 10.0000 60 tablets 14 20 98.00 189710010 CO
63 Carbamazepine 200mg tablet, 28 tablets
1 489 530 Pharmacare Limited V2205 Degranol 200mg Tabs 28 B/B
R 12.9732 28 tablets 14 80 95.00 181892375 PG
64 Carbamazepine 200mg tablet, 56 tablets
3 530 532 Pharmacare Limited V2205 Degranol 200mg Tabs 56 B/B
R 18.8500 56 tablets 14 40 95.00 180339414 PG
65 Carbamazepine 200mg tablet, 84 tablets
278 761 Pharmacare Limited V2205 Degranol 200mg Tabs 84 B/B
R 27.0700 84 tablets 14 40 95.00 180339437 PG
66 Carbamazepine 200mg tablet, 100 tablets
397 861 Pharmacare Limited V2205 Degranol 200mg Tabs 100
R 36.2500 100 tablets 14 20 95.00 189710219 CO
68 Carbidopa 25mg and levodopa 100mg tablet, 100 tablets
157 979 Pharmacare Limited V2205 Carbilev 25/100mg Tabs 100
R 80.3700 100 tablets 14 10 95.00 189710283 CO
Page 4 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
69 Carbidopa 25mg and levodopa 250mg tablet, 100 tablets
31 862 Pharmacare Limited V2205 Carbilev 25/250mg Tabs 100
R 139.0800 100 tablets 14 10 95.00 189710383 CO
71 Carvedilol 6,25mg scored tablet, 28 tablets
926 465 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Carloc 6.25 R 9.7300 30 tablets 14 120 units 99.00 180254416 CO
72 Carvedilol 12,5mg scored tablet, 28 tablets
535 650 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Carloc 12.5 R 12.8400 30 tablets 14 100 units 99.00 180256023 CO
73 Carvedilol 25mg scored tablet, 28 tablets
1 958 558 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Carloc 25 R 17.7600 30 tablets 14 100 units 99.00 180155487 CO
74 Cetirizine 10mg tablet, 28 tablets
2 073 312 Austell Laboratories (Pty) Ltd
V1A10 Austell Cetirizine 10mg
R 2.9840 28 tablets 14 100 99.00 189763014 CO
76 Chloroquine equivalent to Chloroquine base 150mg tablet, 100 tablets
175 812 Zentiva South Africa (Pty) Ltd
VBVW0 Nivaquine Tablets R 68.2500 100 tablets 14 10 94.00 189712624 CO
77 Chlorphenamine 4mg tablet, 10 tablets
7 995 265 Adcock Ingram Healthcare (Pty) Ltd
V2272 Allergex 10 R 1.2300 10 tablets 14 1 shipper (450 packs)
95.00 181821882 PG
78 Chlorphenamine 4mg tablet, 30 tablets
5 329 102 Adcock Ingram Healthcare (Pty) Ltd
V2272 Allergex 30 R 1.9800 30 tablets 14 1 shipper (390 packs)
95.00 181917348 CO
79 Chlorpromazine 25mg tablet, 28 tablets
279 593 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 25 R 11.0400 28 tablets 14 10 94.00 181868871 CO
80 Chlorpromazine 25mg tablet, 56 tablets
118 359 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 25 R 14.9200 56 tablets 14 10 94.00 181868872 CO
82 Chlorpromazine 50mg tablet, 56 tablets
297 309 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 50 R 26.8600 56 tablets 14 10 94.00 181917351 CO
83 Chlorpromazine 100mg tablet, 28 tablets
427 228 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 100 R 22.6400 28 tablets 14 10 94.00 189711825 CO
84 Chlorpromazine 100mg tablet, 56 tablets
256 061 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 100 R 40.8900 56 tablets 14 10 94.00 189711826 CO
85 Chlorpromazine 100mg tablet, 84 tablets
163 200 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Largactil 100 R 58.5500 84 tablets 14 10 94.00 189711834 CO
Page 5 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
86 Chlorpheniramine maleate 4mg tablet, 1000 tablets
12 890 Ranbaxy Pharmaceuticals (Pty) Ltd
V4728 Rhineton 4mg R 150.4800 1000 tablets 14 4 94.00 189751769 CO
89 Citalopram 20mg tablet, 28 tablets
2 289 901 Biotech Laboratories (Pty) Ltd
VUV35 Bio Citalopram 20 Tablets 30's
R 8.0000 30 tablets 14 20 98.00 181798136 CO
90 Clomipramine 25mg tablets, 50 tablets
13 945 Novartis South Africa (Pty) Ltd
VBVW2 Anafranil 25mg tablets
R 100.0000 50 tablets 14 1 93.00 181797926 CO
91 Clonazepam 0,5mg tablet, 84 tablets
293 365 Roche Products (Pty) Ltd
V2177 Rivotril 0.5mg Tablets
R 34.5300 90 tablets 14 1 pack of 90 tablets
93.00 180000664 CO
92 Clonazepam 2mg tablet, 84 tablets
Product AwardedClonazepam 2mg tablet, Deviation: Pack Size: 100 tablets
142 879 Roche Products (Pty) Ltd
V2177 Rivotril 2mg Tablets
R 79.3000 100 tablets 14 1 pack of 100 tablets
93.00 189752192 CO
97 Clozapine 25mg tablet, 84 tablets
Product AwardedClozapine 25mg tablet, Deviation: Pack Size: 100 tablets
87 306 Pharmacare Limited V2205 Aspen Clozapine 25mg Tabs 100
R 36.1038 100 tablets 14 20 95.00 189710069 CO
98 Clozapine 100mg tablet, 84 tablets
Product AwardedClozapine 100mg tablet, Deviation: Pack Size : 100 tablets
184 001 Pharmacare Limited V2205 Aspen Clozapine 100mg Tabs 100
R 115.5960 100 tablets 14 20 95.00 189710025 CO
99 Codeine phosphate 30mg tablet, 100 tablets
14 841 Pharmacare Limited V2205 A-Lennon Codeine Phosphate 30mg Tabs 100
R 414.6000 100 tablets 14 2 95.00 189759809 CO
101 Cyclizine 50mg tablet, 10 tablets
9 900 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Cyclizine 50mg
R 5.6600 10 tablets 14 1 shipper (450 Packs)
95.00 189711824 CO
102 Danazol 100mg capsule, 60 capsules
1 610 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Danogen-100 R 176.0000 60 capsules 14 5 99.00 180280770 CO
Page 6 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
103 Deferasirox 250mg dispersible tablet, 28 tablets
830 Novartis South Africa (Pty) Ltd
VBVW2 Exjade 250mg tablets
R 2 008.7800 28 tablets 14 1 93.00 181810861 CO
104 Deferasirox 500mg dispersible tablet, 28 tablets
1 970 Novartis South Africa (Pty) Ltd
VBVW2 Exjade 500mg tablets
R 4 017.5500 28 tablets 14 1 93.00 181810862 CO
106 Desmopressin 0,1mg tablet, 30 tablets
12 885 Ferring Pharmaceutical (Pty) Ltd
VXY92 DDAVP 0.1mg tablets
R 249.3600 30 tablets 14 5 90.00 180772047 CO
107 Desmopressin 0,2mg tablet, 30 tablets
3 846 Ferring Pharmaceutical (Pty) Ltd
VXY92 DDAVP 0.2mg tablets
R 409.2300 30 tablets 14 5 90.00 181795796 CO
111 Diazepam 5mg scored tablet, 100 tablets
74 205 Roche Products (Pty) Ltd
V2177 Valium 5mg R 57.0000 100 tablets 14 1 pack of 100 tablets
93.00 180280749 CO
114 Diclofenac sodium 25mg enteric coated tablet, 500 tablets
40 430 Mylan (Pty) Ltd V3PS6 Mylan Diclofenac 25mg
R 42.1100 500 tablets 14 1 98.00 189710665 CO
116 Digoxin 0,25mg tablet, 14 tablets
534 014 Pharmacare Limited V2205 Purgoxin 0.25mg Tabs 14 B/B
R 10.5222 14 tablets 14 100 95.00 180323803 PG
117 Digoxin 0,25mg tablet, 28 tablets
899 761 Pharmacare Limited V2205 Purgoxin 0.25mg Tabs 28 B/B
R 14.3754 28 tablets 14 80 95.00 180323807 PG
119 Dinoprostone 0,5mg scored tablet, 10 tablets
7 003 Pfizer Laboratories (Pty) Ltd
V2189 Prostin E2 0.5mg Tab 10's
R 244.4000 10 tablets 14 1 93.00 189710531 CO
120 Domperidone 10mg film coated tablet, 100 tablets
7 490 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Domperidone 10 Tablets 100's
R 30.0000 100 tablets 14 120 x 100's 98.00 189710374 CO
121 Doxazosin 1mg tablet, 30 tablets
16 120 Mylan (Pty) Ltd V3PS6 Cardugen 1mg R 15.0400 30 tablets 14 10 98.00 189763011 CO
123 Doxazosin 4mg tablet, 30 tablets
207 368 Mylan (Pty) Ltd V3PS6 Cardugen 4mg R 28.5000 30 tablets 14 10 98.00 189763013 CO
125 Enalapril 5mg tablet,28 tablets
3 545 317 75% Pharmaceutical Contractors (Pty) Ltd
VCJF7 Hypace 5mg 28's R 3.0300 28 tablets 28 650 91.00 189710188 CO
125 Enalapril 5mg tablet, 28 tablets
1 181 772 25% Austell Laboratories (Pty) Ltd
V1A10 Austell Enalapril 5mg
R 3.4200 28 tablets 14 480 87.42 189710188 CO
Page 7 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
126 Enalapril 10mg tablet, 28 tablets
15 228 702 27% Pharmacare Limited V2205 Pharmapress 10mg Tabs 28
R 4.5500 28 tablets 14 260 87.59 189708531 CO
126 Enalapril 10mg tablet, 28 tablets
14 664 676 26% Dezzo Trading 392 (Pty) Ltd
V05Y6 Enalapril Maleate 10mg - hexal
R 4.5500 28 tablets 14 200 87.59 189708531 CO
126 Enalapril 10mg tablet, 28 tablets
14 100 650 25% Austell Laboratories (Pty) Ltd
V1A10 Austell Enalapril 10mg
R 4.2040 28 tablets 14 480 99.00 189708531 CO
126 Enalapril 10mg tablet, 28 tablets
12 408 572 22% Akacia Healthcare (Pty) Ltd
V0DM6 Envas 10 R 5.0500 30 tablets 14 1 71.89 189708531 CO
127 Enalapril 20mg tablet, 28 tablets
7 038 095 75% Pharmacare Limited V2205 Pharmapress 20mg Tabs 28
R 7.4500 28 tablets 14 260 72.44 189710187 CO
127 Enalapril 20mg tablet, 28 tablets
2 346 032 25% Austell Laboratories (Pty) Ltd
V1A10 Austell Enalapril 20mg
R 5.9570 28 tablets 14 480 99.00 189710187 CO
129 Ferrous salt, providing 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 28 tablets/capsules Must be registered with the MCC
Product awardedFerrous Sulfate Co tablet, 28 tabletsDeviation: Contains 55mg elemental iron
8 228 571 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Ferrous Sulphate Compound Tablets
R 3.4800 28 tablets 14 900 98.00 181923348 CO
Page 8 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
130 Ferrous salt, providing 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 56 tablets/capsules Must be registered with the MCC
Product awardedFerrous Sulfate Co tablet, 56 tabletsDeviation: Contains 55mg elemental iron
771 428 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Ferrous Sulphate Compound Tablets
R 6.2900 56 tablets 14 900 98.00 181923349 CO
131 Ferrous salt, providing 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 84 tablets/capsules Must be registered with the MCC
Product awardedFerrous Sulfate Co tablet, 84 tabletsDeviation: Contains 55mg elemental iron
2 400 000 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Ferrous Sulphate Compound Tablets
R 8.7600 84 tablets 14 750 98.00 181923350 CO
132 Ferrous salt, providing 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 100 tablets/capsules Must be registered with the MCC
Product awardedFerrous Sulfate Co tablet, 100 tabletsDeviation: Contains 55mg elemental iron
226 545 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Ferrous Sulphate Compound Tablets
R 11.4600 100 tablets 14 100 98.00 181892378 CO
Page 9 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
136 Fluoxetine 20mg tablet/capsule, 28 tablets/capsules
Product awardedFluoxetine 20 mg capsule, 28 capsules
1 294 131 Dezzo Trading 392 (Pty) Ltd
V05Y6 Prolax Capsules R 6.0000 28 capsules 14 150 95.00 189712353 CO
137 Fluoxetine 20mg tablets/capsules, 100 tablets/capsules
Product awardedFluoxetine 20 mg capsule, 100 capsules
281 447 Dezzo Trading 392 (Pty) Ltd
V05Y6 Prolax Capsules R 21.6300 100 capsules 14 100 95.00 180106075 CO
138 Folic acid 5mg tablet, 28 tablets MCC registration
8 639 742 33% Gulf Drug Company (Pty) Ltd
VTS03 Gulf Folic Acid 5 R 3.7100 28 tablets 14 900 98.00 189713751 CO
138 Folic acid 5mg tablet,28 tabletsMCC registration
7 464 000 29% Ranbaxy Pharmaceuticals (Pty) Ltd
V4728 Be-Tabs Folic Acid 5mg
R 8.2000 28 tablets 14 250 -14.92 189713751 CO
139 Folic acid 5mg tablet, 100 tablets MCC registration
691 708 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Folic Acid 5 R 15.3900 100 tablets 14 252 98.00 189757933 CO
140 Folic acid 5mg tablet, 1000 tabletsMCC registration
85 770 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Folic Acid 5 R 165.3000 1000 tablets 14 40 98.00 189760407 CO
141 Furosemide 40mg tablet, 28 tablets
7 150 013 Austell Laboratories (Pty) Ltd
V1A10 Austell Furosemide 40mg
R 2.7890 28 tablets 14 100 99.00 180339712 PG
142 Furosemide 40mg tablet, 56 tablets
2 056 598 Austell Laboratories (Pty) Ltd
V1A10 Austell Furosemide 40mg
R 5.5300 56 tablets 14 100 99.00 181798154 PG
143 Furosemide 40mg tablet, 84 tablets
398 401 Austell Laboratories (Pty) Ltd
V1A10 Austell Furosemide 40mg
R 7.4100 84 tablets 14 80 99.00 181798156 PG
144 Furosemide 40mg tablet, 112 tablets
168 328 Austell Laboratories (Pty) Ltd
V1A10 Austell Furosemide 40mg
R 11.5140 112 tablets 14 100 99.00 181859966 PG
145 Furosemide 40mg tablet, 250 tablets
62 886 Mylan (Pty) Ltd V3PS6 Mylan Furosemide 40mg
R 28.5000 250 tablets 14 10 98.00 189711054 CO
146 Furosemide 40mg tablet, 1000 tablets
5 730 Mylan (Pty) Ltd V3PS6 Mylan Furosemide 40mg
R 114.0800 1000 tablets 14 1 98.00 189714165 CO
Page 10 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
147 Furosemide 40mg tablet, 5000 tablets
2 610 Mylan (Pty) Ltd V3PS6 Mylan Furosemide 40mg
R 540.8600 5000 tablets 14 1 98.00 189715350 CO
148 Furosemide 500mg tablet, 100 tablets
6 853 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Lasix 500mg R 833.3200 100 tablets 14 10 94.00 189710019 CO
149 Gabapentin 100mg capsule, 100 capsules
41 700 Biotech Laboratories (Pty) Ltd
VUV35 Biotech Gabapentin 100mg 100's
R 47.5000 100 capsules 14 100 x 100's 98.00 180103509 CO
150 Glibenclamide 5mg tablet, 28 tablets
1 269 072 60% Pharmacare Limited V2205 Glycomin 5mg Tabs 28 B/B
R 3.8000 28 tablets 14 240 95.00 180189209 PG
150 Glibenclamide 5mg tablet,28 tablets
846 048 40% Biotech Laboratories (Pty) Ltd
VUV35 Bio-Glibenclamide 5 Tablets 28's PRP
R 4.0500 28 tablets 14 400 x 28's 92.08 180189209 PG
151 Glibenclamide 5mg tablet, 56 tablets
1 231 189 60% Pharmacare Limited V2205 Glycomin 5mg Tabs 56 B/B
R 5.8000 56 tablets 14 140 95.00 180340162 PG
151 Glibenclamide 5mg tablet, 56 tablets
820 793 40% Biotech Laboratories (Pty) Ltd
VUV35 Bio-Glibenclamide 5 Tablets 56's PRP
R 6.0500 56 tablets 14 400 x 56's 94.12 180340162 PG
152 Glibenclamide 5mg tablet, 84 tablets
682 515 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Glibenclamide 5 Tablets 84's PRP
R 7.8000 84 tablets 14 400 x 84's 98.00 180340166 PG
153 Glibenclamide 5mg tablet, 100 tablets
68 814 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Glibenclamide 5 Tablets 100's
R 10.7000 100 tablets 14 360 x 100's 98.00 189710395 CO
154 Gliclazide 80mg tablet, 28 tablets
693 246 Austell Laboratories (Pty) Ltd
V1A10 Austell Gliclazide 80mg Tablets
R 10.1200 28 tablets 14 720 99.00 180106076 CO
155 Gliclazide 80mg tablet, 56 tablets
2 064 564 Austell Laboratories (Pty) Ltd
V1A10 Austell Gliclazide 80mg Tablets
R 18.2750 56 tablets 14 300 99.00 180670486 CO
156 Gliclazide 80mg tablet, 112 tablets
157 Gliclazide 80mg tablet, 504 tablets
158 Glimepiride 1mg tablet, 28 tablets
1 885 370 Austell Laboratories (Pty) Ltd
V1A10 Austell Glimepiride 1mg
R 2.6930 30 tablets 14 100 99.00 181892379 CO
TO FOLLOW
TO FOLLOW
Page 11 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
159 Glimepiride 2mg tablet,28 tablets
3 149 413 Austell Laboratories (Pty) Ltd
V1A10 Austell Glimepiride 2mg
R 3.8180 30 tablets 14 100 99.00 181892380 CO
160 Glimepiride 4mg tablet, 28 tablets
1 276 008 Austell Laboratories (Pty) Ltd
V1A10 Austell Glimepiride 4mg
R 4.6000 30 tablets 14 100 99.00 181892381 CO
162 Haloperidol 0,5mg capsule, 56 capsules
267 996 Pfizer Laboratories (Pty) Ltd
V2189 Serenace 0.5mg Cap 60s
R 82.1300 60 capsules 14 1 93.00 189710286 CO
163 Haloperidol 1,5mg tablet, 100 tablets
227 334 Pharmacare Limited V2205 Tamide 1.5mg Tabs 100
R 17.6700 100 tablets 14 60 95.00 189710367 CO
167 Haloperidol 5mg tablet, 100 tablets
390 067 Pharmacare Limited V2205 Tamide 5mg Tabs 100
R 28.5000 100 tablets 14 40 95.00 189710327 CO
169 Hydralazine 25mg tablet,56 tablets
876 078 Sandoz SA (Pty) Ltd VVZ69 Hydralazine HCl 25mg 56
R 24.8200 56 tablets 14 100 94.00 181798157 PG
170 Hydralazine 25mg tablet, 84 tablets
79 980 Sandoz SA (Pty) Ltd VVZ69 Hydralazine HCl 25mg 84
R 34.9400 84 tablets 14 100 94.00 180091224 CO
174 Hydrochlorothiazide 12,5mg tablet, 28 tablets
47 628 025 Pharmacare Limited V2205 Ridaq 12.5mg Tabs 28
R 3.5226 28 tablets 14 240 95.00 181821883 PG
175 Hydrochlorothiazide 25mg tablet, 28 tablets
25 612 382 Pharmacare Limited V2205 Ridaq 25mg Tabs 28
R 3.8874 28 tablets 14 240 95.00 180190405 PG
177 Hydrochlorothiazide 25mg tablet, 500 tablets
4 300 Pharmacare Limited V2205 Ridaq 25mg Tabs 500
R 66.1086 500 tablets 14 15 95.00 189710322 CO
178 Hydrocortisone 10mg scored tablet, 100 tablets
21 730 Adcock Ingram Healthcare (Pty) Ltd
V2272 Covocort tablets R 117.0908 100 tablets 14 1 shipper (50 packs)
95.00 189710516 CO
179 Hyoscine butylbromide 10mg tablet, 10 tablets
5 975 242 Pharmacare Limited V2205 Hyospasmol 10mg Tabs 10 B/B
R 33.2196 10 tablets 14 40 95.00 189711820 CO
Page 12 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
180 Hyoscine butylbromide 10mg tablet, 100 tablets
43 496 Pharmacare Limited V2205 Hyospasmol 10mg Tabs 100
R 238.2030 100 tablets 14 5 95.00 189712129 CO
182 Ibuprofen 200mg tablet, 15 tablets
11 622 687 50% Adcock Ingram Healthcare (Pty) Ltd
V2272 Betagesic 15's R 2.0900 15 tablets 14 1 shipper (240 packs)
95.00 180339460 PG
182 Ibuprofen 200mg tablet, 15 tablets
8 833 242 38% Gulf Drug Company (Pty) Ltd
VTS03 Ibunate R 2.2800 15 tablets 14 900 89.82 180339460 PG
182 Ibuprofen 200mg tablet, 15 tablets
2 789 445 12% Dezzo Trading 392 (Pty) Ltd
V05Y6 Ibusor 200 R 2.4600 15 tablets 14 1080 79.07 180339460 PG
183 Ibuprofen 200mg tablet, 42 tablets
2 034 285 61% Gulf Drug Company (Pty) Ltd
VTS03 Ibunate R 5.1000 42 tablets 14 900 98.00 181798173 PG
183 Ibuprofen 200mg tablet, 42 tablets
1 296 184 39% Dezzo Trading 392 (Pty) Ltd
V05Y6 Ibusor 200 R 5.9200 42 tablets 14 100 80.53 181798173 PG
184 Ibuprofen 200mg tablet, 84 tablets
1 398 571 58% Gulf Drug Company (Pty) Ltd
VTS03 Ibunate R 9.1100 84 tablets 14 750 98.00 180339461 PG
184 Ibuprofen 200mg tablet, 84 tablets
1 012 577 42% Dezzo Trading 392 (Pty) Ltd
V05Y6 Ibusor 200 R 10.7000 84 tablets 14 240 79.29 180339461 PG
185 Ibuprofen 200mg tablet, 1000 tablets
186 Ibuprofen 400mg tablet, 15 tablets
1 657 977 Medicine Developers International (Pty) Ltd
V3LJ8 Bren-400 R 4.0600 15 tablets 14 720 95.00 181923355 CO
187 Ibuprofen 400mg tablet, 30 tablets
92 880 Austell Laboratories (Pty) Ltd
V1A10 Austifen 400 R 7.4100 30 tablets 14 300 99.00 181923356 CO
188 Ibuprofen 400mg tablet, 84 tablets
387 629 Medicine Developers International (Pty) Ltd
V3LJ8 Bren-400 R 17.3100 84 tablets 14 160 95.00 189711816 CO
189 Ibuprofen 400mg tablet, 100 tablets
41 970 Medicine Developers International (Pty) Ltd
V3LJ8 Bren-400 R 20.4600 100 tablets 14 160 95.00 180155533 CO
190 Indomethacin 25mg capsule, 100 capsules
495 920 Gulf Drug Company (Pty) Ltd
VTS03 Gulf Indomethacin 25
R 13.1100 100 capsules 14 500 98.00 189714494 CO
TO FOLLOW
Page 13 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
191 Isosorbide dinitrate 5mg sublingual tablet, 50 tablets
766 067 Sandoz SA (Pty) Ltd VVZ69 Isosorbide Dinitrate 5mg 50
R 8.9300 50 tablets 14 100 94.00 189710453 CO
192 Isosorbide dinitrate 10mg tablet, 50 tablets
1 700 Sandoz SA (Pty) Ltd VVZ69 Isosorbide Dinitrate 10mg 50
R 19.0500 50 tablets 14 100 94.00 189710403 CO
193 Isosorbide dinitrate 10mg tablet, 84 tablets
306 888 Sandoz SA (Pty) Ltd VVZ69 Isosorbide Dinitrate 10mg 84
R 14.6600 84 tablets 14 100 94.00 180146434 CO
198 Isotretinoin 10mg capsule, 60 capsules
2 250 Litha Pharma (Pty) Ltd VGS73 Orantane 10mg R 142.5000 60 capsules 14 8 94.00 189712676 CO
199 Isotretinoin 20mg capsule, 60 capsules
5 490 Litha Pharma (Pty) Ltd VGS73 Oratane 20mg R 218.0000 60 capsules 14 6 94.00 189712688 CO
203 Lamotrigine 25mg tablet, 56 tablets
170 012 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Epitec 25 R 25.5000 60 tablets 14 180 units 99.00 180108134 CO
204 Lamotrigine 50mg tablet, 56 tablets
161 223 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Epitec 50 R 36.6600 60 tablets 14 180 units 99.00 180108137 CO
205 Lamotrigine 100mg tablet, 56 tablets
202 091 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Epitec 100 R 57.1100 60 tablets 14 80 units 99.00 180108130 CO
206 Lamotrigine 200mg tablet, 56 tablets
12 930 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Epitec 200 R 104.8600 60 tablets 14 70 units 99.00 180192399 CO
208 Lansoprazole 30mg capsule, 14 capsules
1 344 000 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Lansoloc 30 (14's)
R 6.9500 14 capsules 14 240 units 99.00 180053598 CO
209 Lansoprazole 30mg capsule, 28 capsules
3 120 000 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Lansoloc 30 (30's)
R 12.1800 30 capsules 14 180 units 99.00 181814080 CO
210 Leflunomide 10mg tablet, 30 tablets
740 Adcock Ingram Healthcare (Pty) Ltd
V2272 Rheumalef 10mg R 352.8329 30 tablets 14 1 shipper (150 packs)
95.00 181753191 CO
211 Leflunomide 20mg tablet, 30 tablets
12 875 Adcock Ingram Healthcare (Pty) Ltd
V2272 Rheumalef 20mg R 352.8329 30 tablets 14 1 shipper (150 packs)
95.00 181781164 CO
212 Levetiracetam 250mg tablet, 30 tablets
14 180 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Redilev 250 R 37.6200 30 tablets 14 5 90.00 181934912 CO
Page 14 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
215 Levetiracetam 750mg tablet, 30 tablets
8 830 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Redilev 750 R 91.2000 30 tablets 14 5 90.00 181934915 CO
216 Levothyroxine sodium 0,05mg tablet, 28 tablets
755 831 Merck (Pty) Ltd V3018 Euthyrox 50ug 28's
R 5.0400 28 tablets 14 180 95.00 181860085 CO
217 Levothyroxine sodium 0,05mg tablet, 100 tablets
86 879 Merck (Pty) Ltd V3018 Euthyrox 50ug 100's
R 15.7500 100 tablets 14 180 95.00 189710425 CO
218 Levothyroxine sodium 0,1mg tablet, 28 tablets
804 118 Merck (Pty) Ltd V3018 Euthyrox 100ug 28's
R 6.9600 28 tablets 14 180 95.00 181860086 CO
219 Levothyroxine sodium 0,1mg tablet, 100 tablets
79 120 Merck (Pty) Ltd V3018 Euthyrox 100ug 100's
R 22.1000 100 tablets 14 180 95.00 189710280 CO
221 Lithium carbonate 250mg tablet, 100 tablets
82 191 Pharmacare Limited V2205 Camcolit 250mg Tabs 100
R 160.7628 100 tablets 14 5 95.00 189710365 CO
222 Lithium carbonate 400mg tablet, 100 tablets
34 037 Pharmacare Limited V2205 Camcolit 400mg Tabs 100
R 223.2576 100 tablets 14 5 95.00 189710053 CO
223 Loperamide 2mg tablet, 6 tablets
4 531 830 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Loperamide 2mg 6's
R 1.2700 6 tablets 14 1 shipper (176 packs)
95.00 189710479 CO
224 Loperamide 2mg tablet, 300 tablets
27 010 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Loperamide 2mg 300's
R 22.4600 300 tablets 14 1 shipper (105 packs0
95.00 189710482 CO
225 Lorazepam 1mg tablet, 100 tablets
85 515 Pharmacare Limited V2205 Tranqipam 1mg Tabs 100
R 94.5858 100 tablets 14 10 95.00 189710157 CO
226 Lorazepam 2,5mg tablet, 100 tablets
26 364 Pharmacare Limited V2205 Tranqipam 2.5mg Tabs 100
R 148.1088 100 tablets 14 10 95.00 189714603 CO
227 Losartan 50mg tablet, 28 tablets
564 209 Austell Laboratories (Pty) Ltd
V1A10 Austell Losartan 50
R 7.6930 28 tablets 14 100 99.00 181936086 CO
228 Losartan 100mg tablet, 28 tablets
39 788 Austell Laboratories (Pty) Ltd
V1A10 Austell Losartan 100
R 14.9060 28 tablets 14 100 99.00 181936085 CO
Page 15 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
229 Magnesium chloride 500mg - 700mg slow release tablet, 60 tablets
Product awardedMagnesium Chloride 660mg tablet, 60 tablets
256 637 Mirren (Pty) Ltd V7149 Ultimag Tablets R 19.1200 60 tablets 14 100 90.00 180282649 CO
230 Mesalazine 400mg tablet, 90 tablets
25 349 Equity Pharmaceuticals (Pty) Ltd
V1QZ3 Asacol Tablets R 206.7500 90 tablets 14 20 90.00 189762990 CO
232 Metformin 500mg tablet,56 tablets
6 323 765 80% Austell Laboratories (Pty) Ltd
V1A10 Austell Metformin 500mg Tablets
R 8.3220 56 tablets 14 300 99.00 180670492 PG
232 Metformin 500mg tablet, 56 tablets
233 Metformin 500mg tablet, 84 tablets
2 886 446 60% Austell Laboratories (Pty) Ltd
V1A10 Austell Metformin 500mg Tablets
R 12.3550 84 tablets 14 240 99.00 180339480 PG
233 Metformin 500mg tablet, 84 tablets
1 924 297 40% Mylan (Pty) Ltd V3PS6 Mylan Metformin 500mg
R 12.5000 84 tablets 14 10 96.94 180339480 PG
234 Metformin 500mg tablet, 500 tablets
135 130 Mylan (Pty) Ltd V3PS6 Mylan Metformin 500mg
R 63.1600 500 tablets 14 1 98.00 189710513 CO
235 Metformin 850mg tablet, 28 tablets
236 Metformin 850mg tablet, 56 tablets
4 809 090 70% Austell Laboratories (Pty) Ltd
V1A10 Austell Metformin 850mg Tablets
R 11.9700 60 tablets 14 420 99.00 180670494 PG
236 Metformin 850mg tablet, 56 tablets
2 061 039 30% Mylan (Pty) Ltd V3PS6 Mylan metformin 850mg
R 12.8000 56 tablets 14 10 91.76 180670494 PG
237 Metformin 850mg tablet, 84 tablets
652 878 Mylan (Pty) Ltd V3PS6 Mylan Metformin 850mg
R 18.1700 84 tablets 14 10 98.00 189711808 CO
238 Metformin 850mg tablet, 300 tablets
88 800 Mylan (Pty) Ltd V3PS6 Mylan Metformin 850mg
R 62.7700 300 tablets 14 1 98.00 189710233 CO
239 Methyldopa 250mg tablet, 56 tablets
1 101 598 Pharmacare Limited V2205 Hy-Po-Tone 250mg Tabs 56
R 40.9716 56 tablets 14 25 95.00 189711810 CO
240 Methyldopa 250mg tablet, 84 tablets
1 030 009 Pharmacare Limited V2205 Hy-Po-Tone 250mg Tabs 84
R 56.5668 84 tablets 14 15 95.00 189710812 CO
242 Methylphenidate 10mg tablet, 30 tablets
705 550 Novartis South Africa (Pty) Ltd
VBVW2 Ritalin 10mg R 24.6200 30 tablets 14 1 93.00 189710452 CO
TO FOLLOW
TO FOLLOW
Page 16 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
243 Methylphenidate 20mg, modified release tablet/capsule, 30 tablets/capsules
Product AwardedMethylphenidate 20mg, modified release capsule, 30 capsules
150 059 Novartis South Africa (Pty) Ltd
VBVW2 Ritalin LA 20mg R 110.4700 30 capsules 14 1 93.00 181769645 CO
244 Methylphenidate 30mg, modified release tablet/capsule, 30 tablets/capsules
Product AwardedMethylphenidate 30mg, modified release capsule, 30 capsules
53 987 Novartis South Africa (Pty) Ltd
VBVW2 Ritalin LA 30mg R 183.9800 30 capsules 14 1 93.00 181769646 CO
245 Metoclopramide 10mg tablet, 10 tablets
2 903 207 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Contromet 10mg 10's
R 1.9300 10 tablets 14 1 shipper (450 packs)
95.00 181798176 PG
246 Metoclopramide 10mg tablet, 100 tablets
128 421 Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Contromet 10mg 100's
R 8.4600 100 tablets 14 1 shipper (100 packs)
95.00 189711057 CO
247 Metoclopramide 10mg tablet, 500 tablets
10 611 Medicine Developers International (Pty) Ltd
V3LJ8 Clomax R 35.3400 500 tablets 14 72 95.00 189750564 CO
251 Midazolam 7,5mg tablet, 20 tablets
1 000 Roche Products (Pty) Ltd
V2177 Dormicum 7.5mg R 77.6100 20 tablets 14 1 pack of 20 tablets
93.00 181751133 CO
252 Midazolam 15mg tablet, 20 tablets
2 115 Roche Products (Pty) Ltd
V2177 Dormicum 15mg R 112.0000 20 tablets 14 1 pack of20 tablets
93.00 180190409 CO
254 Minoxidil 5mg tablet, 100 tablets
11 442 Pfizer Laboratories (Pty) Ltd
V2189 Loniten 5mg Tab, 100's
R 314.3300 100 tablets 14 1 93.00 189714350 CO
255 Minoxidil 10mg tablet, 100 tablets
3 554 Pfizer Laboratories (Pty) Ltd
V2189 Loniten 10mg Tab, 100's
R 550.0000 100 tablets 14 1 93.00 189714351 CO
256 Montelukast 4mg chewable tablet, 28 tablets
5 606 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Topraz 4 R 30.7800 28 tablets 14 5 90.00 181789304 CO
Page 17 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
257 Montelukast 5mg chewable tablet, 28 tablets
14 375 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Topraz 5 R 34.2000 28 tablets 14 5 90.00 180344234 CO
258 Montelukast 10mg tablet, 28 tablets
17 853 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Topraz 10 R 42.1800 28 tablets 14 5 90.00 180344233 CO
259 Morphine 10mg modified release tablet, 60 tablets
34 828 Akacia Healthcare (Pty) Ltd
V0DM6 SRM Rhotard 10 R 127.1400 60 tablets 14 1 90.00 180105359 CO
260 Morphine 30mg modified release tablet, 60 tablets
44 573 Akacia Healthcare (Pty) Ltd
V0DM6 SRM Rhotard 30 R 200.0200 60 tablets 14 1 90.00 180105391 CO
263 Nicotinamide 100mg tablet,28 tablets
336 074 Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Nicotinamide 100mg tablets
R 5.8400 28 tablets 14 1000 99.00 180339515 PG
264 Nicotinamide 100mg tablet, 84 tablets
44 311 Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Nicotinamide 100mg tablets
R 14.2200 84 tablets 14 84 99.00 181917398 CO
265 Nifedipine 5mg capsule, 100 capsules
35 144 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Nifedipine 5 Capsules 100's
R 34.3400 100 capsules 14 10 98.00 189710364 CO
266 Nifedipine 10mg capsule, 100 capsules
46 843 Biotech Laboratories (Pty) Ltd
VUV35 Bio-Nifedipine 10mg Capsules 100's
R 55.7600 100 capsules 14 10 98.00 189710326 CO
267 Nifedipine 30mg modified release tablet, 28 tablets
3 786 267 Biotech Laboratories (Pty) Ltd
VUV35 Bio Nifedipine XL 30 Tablets 30's
R 23.7000 30 tablets 14 400 x 30's 98.00 180012708 CO
268 Nifedipine 60mg modified release tablet, 28 tablets
39 200 Biotech Laboratories (Pty) Ltd
VUV35 Bio Nifedipine XL 60 Tablets 30's
R 41.0000 30 tablets 14 320 x 30's 98.00 180012709 CO
270 Olanzapine 2,5mg tablet, 28 tablets
32 433 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Redilanz 2,5 R 18.2400 28 tablets 14 5 90.00 180959585 CO
271 Olanzapine 5mg tablet, 28 tablets
100 010 Mylan (Pty) Ltd V3PS6 Mylan Olanzapine 5mg
R 24.7300 30 tablets 14 30 98.00 181936077 CO
272 Olanzapine 10mg tablet, 28 tablets
189 976 Mylan (Pty) Ltd V3PS6 Mylan Olanzapine 10mg
R 30.9400 30 tablets 14 30 98.00 181936076 CO
273 Omeprazole 10mg dispersible tablet, 28 tablets
716 849 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Losec Mups 10 R 41.1800 28 tablets 10 10 95.00 181778178 CO
Page 18 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
274 Omeprazole 10mg tablet/capsule, 28 tablets/capsules
Product AwardedOmeprazole 10mg capsule, 30 capsules
162 814 Dr Reddy's Laboratories (Pty) Ltd
V1A08 Omez 10 R 17.6700 30 capsules 14 5 90.00 181936078 CO
276 Omeprazole 20mg capsule, 28 capsules
277 Orphenadrine 50mg tablet, 28 tablets.
2 962 888 Pharmacare Limited V2205 Phenerine 50mg Tabs 28
R 16.5414 28 tablets 14 60 95.00 180339583 CO
278 Orphenadrine 50mg tablet, 56 tablets
1 672 276 Pharmacare Limited V2205 Phenerine 50mg Tabs 56 B/B
R 32.3190 56 tablets 14 40 95.00 180339585 CO
279 Orphenadrine 50mg tablet, 84 tablets
478 352 Pharmacare Limited V2205 Phenerine 50mg Tabs 84 B/B
R 45.2580 84 tablets 14 20 95.00 180339586 CO
280 Oxazepam 10mg tablet, 100 tablets
84 137 Pharmacare Limited V2205 Serepax 10mg Tabs 100
R 38.0760 100 tablets 14 20 95.00 189712225 CO
281 Oxazepam 30mg tablet, 100 tablets
12 521 Pharmacare Limited V2205 Purata 30mg Tabs 100
R 51.0635 100 tablets 14 20 95.00 189714612 CO
282 Oxybutynin 5mg tablet, 84 tablets
Product AwardedOxybutynin 5mg tablet,Deviation: Pack Size:100 tablets
152 515 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Ditropan R 39.9600 100 tablets 14 10 94.00 189710155 CO
283 Pancreatin 150mg equivalent to Amylase 8000 FIP units, Lipase 10000 FIP units and Protease 600 FIP units per capsule, 100 capsules
12 187 Abbott Laboratories (Pty) Ltd
V2150 Creon 10000 R 366.2820 100 capsules 14 1 unit of 100's 92.00 181747895 CO
284 Pancreatin 300mg equivalent to Amylase 18 000 FIP units, Lipase 25000 FIP units and Protease 1000 FIP units per capsule, 100 capsules
15 693 Abbott Laboratories (Pty) Ltd
V2150 Creon 25000 R 714.0618 100 capsules 14 1 unit of 100's 92.00 180231590 CO
TO FOLLOW
Page 19 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
285 Paracetamol 500mg tablet, 20 tablets
43 948 572 52% Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Napamol 20's
R 2.2700 20 tablets 14 1 shipper (240 packs)
95.00 180155484 CO
285 Paracetamol 500mg tablet, 20 tablets
19 438 792 23% Gulf Drug Company (Pty) Ltd
VTS03 Painblok R 2.7100 20 tablets 14 900 80.56 180155484 CO
285 Paracetamol 500mg tablet,20 tablets
11 832 308 14% Austell Laboratories (Pty) Ltd
V1A10 Austell Paracetamol 500mg
R 2.8500 20 tablets 14 320 76.00 180155484 CO
285 Paracetamol 500mg tablet, 20 tablets
9 296 813 11% Innovata Pharmaceuticals (Pty) Ltd
VBBL4 Painogesic R 2.8600 20 tablets 14 1200 74.61 180155484 CO
286 Paracetamol 500mg tablet, 100 tablets
2 354 534 80% Innovata Pharmaceuticals (Pty) Ltd
VBBL4 Painogesic R 9.1800 100 tablets 14 518 98.00 189753434 CO
286 Paracetamol 500mg tablet, 100 tablets
588 633 20% Adcock Ingram Healthcare (Pty) Ltd
V2272 Adco-Napamol 100's
R 10.3300 100 tablets 14 1 shipper (100 packs)
95.00 189753434 CO
287 Paracetamol 500mg tablet, 500 tablets
307 078 Innovata Pharmaceuticals (Pty) Ltd
VBBL4 Painogesic R 36.2900 500 tablets 14 96 98.00 189753433 CO
289 Perindopril 4mg tablet,28 tablets
1 577 000 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Cipla Perindopril 4mg
R 25.4700 30 tablets 14 180 units 99.00 180054705 CO
294 Phenytoin 100mg capsule/tablet, 84 capsules/tablets
Product AwardedPhenytoin 100mg capsule, 84 capsules
2 491 511 Pharmacare Limited V2205 Phenytoin 100mg Caps 84
R 61.4688 84 capsules 14 20 95.00 189711804 CO
295 Phenytoin 100mg capsule/tablet, 100 capsules/tablets
Product AwardedPhenytoin 100mg capsule, 100 capsules
153 700 Pfizer Laboratories (Pty) Ltd
V2189 Epanutin 100mg Cap, 100's
R 85.5000 100 capsules 14 1 93.00 189715312 CO
298 Potassium chloride 600mg tablet, 100 tablets
748 243 Mirren (Pty) Ltd V7149 Ultipot R 54.0000 100 tablets 14 100 90.00 181917399 CO
Page 20 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
300 Pramipexole 0,25mg tablet, 100 tablets
2 510 Gulf Drug Company (Pty) Ltd
VTS03 Oxpola 0.25mg R 159.6000 100 tablets 14 5 98.00 181758021 CO
302 Pravastatin 20mg tablet, 30 tablets
101 203 Accord Healthcare (Pty) Ltd
V2MB8 Pixeta 20mg R 19.9500 30 tablets 14 180 94.00 180230824 CO
312 Pregabalin 25mg capsule, 56 capsules
4 215 Pfizer Laboratories (Pty) Ltd
V2189 Lyrica 25mg Cap, 56's
R 83.0900 56 capsules 14 1 93.00 181842560 CO
313 Pregabalin 75mg capsule, 56 capsules
35 956 Pfizer Laboratories (Pty) Ltd
V2189 Lyrica 75mg Cap, 56's
R 83.0900 56 capsules 14 1 93.00 181831898 CO
316 Promethazine 10mg tablet, 100 tablets
91 822 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Phenergan 10 R 14.1500 100 tablets 14 10 94.00 189710047 CO
317 Promethazine 25mg tablet, 100 tablets
163 450 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Phenergan 25 R 21.8600 100 tablets 14 10 94.00 189710049 CO
319 Propranolol 10mg tablet, 50 tablets
180 891 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Inderal 10 R 45.6000 50 tablets 10 10 95.00 189716004 CO
326 Pyridostigmine 10mg tablet, 50 tablets
23 100 Meda Pharma South Africa (Pty) Ltd
V2ZD6 Mestinon 10mg R 264.6700 50 tablets 90 10 90.00 180000607 CO
327 Pyridostigmine 60mg tablet, 150 tablets
18 617 Meda Pharma South Africa (Pty) Ltd
V2ZD6 Mestinon 60mg R 1 245.5200 150 tablets 90 10 90.00 189710277 CO
328 Pyridoxine (Vitamin B6) 25mg tablet, 28 tablets
8 079 902 65% Pharmachem Laboratories (Pty) Ltd
V3LA8 Egoli Pyridoxine 25mg tablets
R 2.4500 28 tablets 14 2000 85.68 180339610 CO
328 Pyridoxine (Vitamin B6) 25mg tablet, 28 tablets
4 285 714 35% Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Vitamin 6 25mg tablets
R 2.2200 28 tablets 14 1000 99.00 180339610 CO
329 Pyridoxine (Vitamin B6) 25mg tablet, 100 tablets
582 357 Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Vitamin 6 25mg tablets
R 8.1900 100 tablets 14 75 99.00 189710278 CO
330 Quetiapine 25mg tablet, 100 tablets
7 671 Mylan (Pty) Ltd V3PS6 Mylan Quetiapine 25mg
R 50.1600 100 tablets 14 100 98.00 180350983 CO
331 Quetiapine 100mg tablet, 90 tablets
9 286 Mylan (Pty) Ltd V3PS6 Mylan Quetiapine 100mg
R 101.5700 90 tablets 14 90 98.00 180351237 CO
332 Quetiapine 200mg tablet, 60 tablets
13 110 Mylan (Pty) Ltd V3PS6 Mylan Quetiapine 200mg
R 119.1200 60 tablets 14 60 98.00 180351239 CO
Page 21 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
333 Quetiapine 300mg tablet, 60 tablets
4 952 Mylan (Pty) Ltd V3PS6 Mylan Quetiapine 300mg
R 190.9400 60 tablets 14 60 98.00 181772178 CO
334 Quetiapine 50mg modified release tablet, 100 tablets
Product awardedQuetiapine 50mg modified release tabletDeviation: Pack Size: 60 tablets
6 955 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Seroquel XR 50 R 166.5800 60 tablets 10 10 95.00 181867213 CO
335 Quetiapine 200mg modified release tablet, 100 tablets
Product awardedQuetiapine 200mg modified release tabletDeviation: Pack Size: 60 tablets
10 000 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Seroquel XR 200 R 283.9400 60 tablets 10 10 95.00 181867269 BT
336 Quetiapine 300mg modified release tablet, 100 tablets
Product awardedQuetiapine 300mg modified release tabletDeviation: Pack Size: 60 tablets
7 242 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Seroquel XR 300 R 330.9700 60 tablets 10 10 95.00 181867272 BT
337 Quetiapine 400mg modified release tablet, 100 tablets
Product awardedQuetiapine 400mg modified release tabletDeviation: Pack Size: 60 tablets
6 947 AstraZeneca Pharmaceuticals (Pty) Ltd
V2180 Seroquel XR 400 R 399.4800 60 tablets 10 10 95.00 181867216 CO
338 Ranitidine 150mg tablet, 56 tablets
1 620 800 Biotech Laboratories (Pty) Ltd
VUV35 Ranitidine 150 Biotech Tablets 60's
R 13.2000 60 tablets 14 200 x 60's 98.00 189712314 CO
339 Retinol (Vitamin A) 50 000iu snip-off, soft gel capsule, 50 capsules. Colour coded white (opaque)
51 821 Biotech Laboratories (Pty) Ltd
VUV35 Vitaforce A50 000 IU Capsules 50's
R 28.9400 50 capsules 14 20 98.00 181798191 CO
Page 22 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
340 Retinol (Vitamin A) 100 000iu snip-off, soft gel capsule, 50 capsules. Colour coded blue (opaque)
187 053 Biotech Laboratories (Pty) Ltd
VUV35 Vitaforce A100 000 IU Capsules 50's
R 37.2600 50 capsules 14 20 98.00 181798187 CO
341 Retinol (Vitamin A) 200 000iu snip-off, soft gel capsule, 50 capsules. Colour coded red (opaque)
283 320 Biotech Laboratories (Pty) Ltd
VUV35 Vitaforce A200 000 IU Capsules 50's
R 54.8200 50 capsules 14 20 98.00 181798190 CO
342 Risperidone 0,5mg tablet, 28 tablets
241 688 Accord Healthcare (Pty) Ltd
V2MB8 Rispacor 0.5mg R 8.2100 30 tablets 14 50 94.00 181799554 CO
343 Risperidone 1mg tablet, 28 tablets
773 598 Accord Healthcare (Pty) Ltd
V2MB8 Rispacor 1mg R 4.7900 30 tablets 14 50 94.00 180339003 CO
344 Risperidone 2mg tablet, 28 tablets
1 157 261 Accord Healthcare (Pty) Ltd
V2MB8 Rispacor 2mg R 5.5900 30 tablets 14 50 94.00 180965107 CO
345 Risperidone 3mg tablet, 28 tablets
607 261 Accord Healthcare (Pty) Ltd
V2MB8 Rispacor 3mg R 7.7000 30 tablets 14 50 94.00 180964999 CO
346 Ropinirole 0,25mg tablet, 84 tablets
2 573 Accord Healthcare (Pty) Ltd
V2MB8 Accord Ropinirole 0,25mg
R 34.2000 84 tablets 14 12 94.00 181809452 CO
347 Ropinirole 0,5mg tablet,84 tablets
2 875 Accord Healthcare (Pty) Ltd
V2MB8 Accord Ropinirole 0,5mg
R 54.7200 84 tablets 14 12 94.00 181809456 CO
348 Ropinirole 1mg tablet, 84 tablets
3 093 Accord Healthcare (Pty) Ltd
V2MB8 Accord Ropinirole 1mg
R 83.2200 84 tablets 14 12 94.00 181809457 CO
349 Ropinirole 5mg tablet, 84 tablets
2 014 Accord Healthcare (Pty) Ltd
V2MB8 Accord Ropinirole 5mg
R 353.4000 84 tablets 14 12 94.00 181860070 CO
350 Senna extract equivalent to Sennosides A and B 13,5mg tablet, 20 tablets
1 403 068 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Soflax Tablets R 5.0900 20 tablets 14 480 units 99.00 181826115 CO
351 Sevelamer 800mg tablet, 180 tablets
150 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Renvela Tablets R 1 384.2200 180 tablets 14 10 94.00 181846974 CO
352 Sildenafil 20mg tablet, 90 tablets
3 194 Pfizer Laboratories (Pty) Ltd
V2189 Revatio 20mg Tab, 90s
R 2 256.1900 90 tablets 14 1 93.00 181828390 CO
Page 23 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
353 Sildenafil 50mg tablet, 4 tablets
1 600 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Sildenafil Cipla R 12.6100 4 tablets 14 10 units 99.00 180350988 CO
354 Sildenafil 100mg tablet, 4 tablets
880 Pfizer Laboratories (Pty) Ltd
V2189 Avigra 100 R 49.2900 4 tablets 14 1 93.00 180350989 CO
355 Simvastatin 10mg tablet, 28 tablets
8 610 697 60% Austell Laboratories (Pty) Ltd
V1A10 Austell Simvastatin 10mg
R 5.9280 28 tablets 14 600 99.00 189762856 CO
355 Simvastatin 10mg tablet, 28 tablets
5 740 464 40% Cipla Medpro South Africa (Pty) Ltd
VXZ32 Cipla-Simvastatin 10
R 6.1000 28 tablets 14 240 units 96.39 189762856 CO
356 Simvastatin 20mg tablet, 28 tablets
8 851 157 Austell Laboratories (Pty) Ltd
V1A10 Austell Simvastatin 20mg
R 7.6950 28 tablets 14 600 99.00 189762970 CO
357 Spironolactone 25mg tablet, 28 tablets
1 614 762 Pharmacare Limited V2205 Spiractin 25mg Tabs 28
R 10.8300 28 tablets 14 80 95.00 181798184 CO
358 Spironolactone 25mg tablet, 56 tablets
640 116 Sandoz SA (Pty) Ltd VVZ69 Spironolactone 25mg 56
R 20.8400 56 tablets 14 100 94.00 181747912 CO
359 Spironolactone 25mg tablet, 84 tablets
38 068 Pharmacare Limited V2205 Spiractin 25mg Tabs 84
R 37.5972 84 tablets 14 20 95.00 181747914 CO
360 Spironolactone 25mg tablet, 200 tablets
63 657 Sandoz SA (Pty) Ltd VVZ69 Spironolactone 25mg 200
R 76.2000 200 tablets 14 100 94.00 189710245 CO
361 Spironolactone 100mg tablet,60 tablets
11 420 Pharmacare Limited V2205 Spiractin 100mg Tabs 60
R 112.0050 60 tablets 14 10 95.00 189711050 CO
363 Sulfasalazine 500mg tablet, 100 tablets
Product AwardedSulfasalazine 500mg enteric coated tablet, 100 tablets
199 644 Pfizer Laboratories (Pty) Ltd
V2189 Salazopyrin EN 500mg Tab
R 236.4500 100 tablets 14 1 93.00 189714546 CO
364 Tamsulosin 0,4mg capsule, 28 capsules
513 108 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Uromax R 21.4700 30 capsules 14 120 units 99.00 180318479 CO
Page 24 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
365 Theophylline 200mg modified release tablet, 56 tablets
1 995 297 Sandoz SA (Pty) Ltd VVZ69 Theophylline ANH 200mg 60
R 19.0400 60 tablets 14 100 94.00 189762882 CO
367 Theophylline 300mg modified release tablet, 56 tablets
220 639 Sandoz SA (Pty) Ltd VVZ69 Theophylline ANH 300mg 60
R 41.9800 60 tablets 14 100 94.00 189762886 CO
368 Thiamine (Vitamin B1) 100mg tablet, 28 tablets
1 499 904 56% Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Thiamine 100mg tablets
R 7.1300 28 tablets 14 1000 99.00 181798189 CO
368 Thiamine (Vitamin B1) 100mg tablet, 28 tablets
1 163 178 44% Adcock Ingram Healthcare (Pty) Ltd
V2272 Vit B1-100mg 28's R 7.3900 28 tablets 14 1 shipper (192 packs)
91.72 181798189 CO
369 Thiamine (Vitamin B1) 100mg tablet, 84 tablets
105 734 Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Thiamine 100mg tablets
R 17.8800 84 tablets 14 1000 99.00 181917416 CO
370 Thyroxine sodium 0,025mg tablet, 28 tablets
2 575 Merck (Pty) Ltd V3018 Euthyrox 25ug R 3.5000 30 tablets 14 180 95.00 181934919 CO
372 Topiramate 25mg tablet, 56 tablets
42 343 Ranbaxy South Africa (Pty) Ltd
VVZ04 Toplep 25 R 25.0000 60 tablets 14 20 90.00 180208565 CO
373 Topiramate 50mg tablet, 56 tablets
104 174 Ranbaxy South Africa (Pty) Ltd
VVZ04 Toplep 50 R 29.0300 60 tablets 14 20 90.00 180208570 CO
374 Topiramate 100mg tablet, 56 tablets
69 857 Ranbaxy South Africa (Pty) Ltd
VVZ04 Toplep 100 R 46.2800 60 tablets 14 70 90.00 180208573 CO
375 Tramadol 50mg capsule/tablet, 20 capsules/tablets
Product AwardedTramadol 50mg capsule, 20 capsules
1 707 651 Austell Laboratories (Pty) Ltd
V1A10 Austell Tramadol 50mg
R 7.9800 20 capsules 14 500 99.00 180070238 CO
376 Tramadol 50mg capsule/tablet, 100 capsules/tablets
Product AwardedTramadol 50mg capsule, 100 capsules
1 540 786 Austell Laboratories (Pty) Ltd
V1A10 Austell Tramadol 50mg
R 31.9200 100 capsules 14 100 99.00 180155404 CO
Page 25 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
377 Tramadol 100mg capsule/tablet, 60 capsules/tablets
Product AwardedTramadol 100mg tablet, 60 tablets
99 113 Sandoz SA (Pty) Ltd VVZ69 Trama-Hexal SR 100mg 60 Tab FP
R 119.6600 60 tablets 14 100 94.00 181761190 CO
378 Tramadol 200mg capsule/tablet, 60 capsules/tablets
Product AwardedTramadol 200mg tablet, 60 tablets
27 340 Sandoz SA (Pty) Ltd VVZ69 Trama-Hexal SR 200mg 60 Tab FP
R 216.0200 60 tablets 14 100 94.00 181917410 CO
380 Tranexamic acid 500mg tablet,100 tablets
128 710 Pfizer Laboratories (Pty) Ltd
V2189 Cyklokapron T 500mg Tab
R 278.8700 100 tablets 14 1 93.00 189718982 CO
383 Ursodeoxycholic Acid 100mg tablet, 180 tablets
3 647 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Ursotan R 766.3300 180 tablets 14 10 94.00 189715336 CO
385 Valproate sodium 100mg crushable tablet, 100 tablets
33 448 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim 100 Crushable
R 78.7500 100 tablets 14 10 94.00 181808859 CO
386 Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet, 56 tablets
557 976 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 200 R 27.0300 56 tablets 14 10 94.00 181813970 CO
387 Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet, 100 tablets
743 914 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 200 R 42.7000 100 tablets 14 10 94.00 180145714 CO
388 Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet, 56 tablets
1 001 066 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 300 R 38.8200 56 tablets 14 10 94.00 181813972 CO
389 Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet, 100 tablets
797 410 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 300 R 63.0000 100 tablets 14 10 94.00 180145716 CO
Page 26 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
390 Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 56 tablets
634 910 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 500 R 61.1700 56 tablets 14 10 94.00 181813974 CO
391 Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 100 tablets
897 405 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Epilim CR 500 R 99.2600 100 tablets 14 10 94.00 180223205 CO
395 Venlafaxine 37,5mg tablet/capsule, 28 tablets/capsules
Product AwardedVenlafaxine 37,5mg capsule, 30 capsules
3 290 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Venlor XR 37,5 R 39.1700 30 capsules 14 30 99.00 181851983 CO
396 Venlafaxine 75mg tablet/capsule, 28 tablets/capsules
Product AwardedVenlafaxine 75mg capsule, 30 capsules
68 374 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Venlor XR 75 R 39.1700 30 capsules 14 60 99.00 180358280 CO
397 Venlafaxine 150mg tablet/capsule, 28 tablets/capsules
Product AwardedVenlafaxine 150mg capsule, 30 capsules
69 622 Cipla Medpro South Africa (Pty) Ltd
VXZ32 Venlor XR 150 R 68.5000 30 capsules 14 60 99.00 180358282 CO
398 Verapamil 40mg tablet, 84 tablets
185 030 Pharmacare Limited V2205 Vasomil 40mg Tabs 84
R 32.1500 84 tablets 14 30 95.00 180339609 CO
400 Verapamil 240mg tablet, 28 tablets
39 213 Sandoz SA (Pty) Ltd VVZ69 Vera-Hexal 240mg SR 30
R 52.6700 30 tablets 14 100 94.00 189709075 CO
401 Vigabatrin 500mg tablet, 100 tablets
1 850 Sanofi-Aventis South Africa (Pty) Ltd
V2160 Sabril R 897.3700 100 tablets 14 10 94.00 180115255 CO
402 Vit. B6 (Pyridoxine HCl) 25mg tablet, 500 tablets
36 750 Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Vitamin 6 25mg tablets
R 37.2400 500 tablets 14 75 99.00 189710353 CO
Page 27 of 28
HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018
Item No
Item Description Quantity Awarded
% Split Supplier Name Supplier Code
Brand Name Delivered Price
Unit Pack Lead time (Days)
MOQ Total Score
NSN UOM
403 Vitamin B co: Vit. B1 (Thiamine HCL) 5mg, Vit. B2 (Riboflavine) 2mg, Vit. B6 (Pyridoxine HCL) 2mg and Nicotinamide 20mg tablet, 28 tablets
14 966 645 68% Pharmachem Laboratories (Pty) Ltd
V3LA8 Egoli Vitamin B Complex Strong tablets
R 1.6500 28 tablets 14 1600 95.00 180339611 CO
403 Vitamin B co: Vit. B1 (Thiamine HCL) 5mg, Vit. B2 (Riboflavine) 2mg, Vit. B6 (Pyridoxine HCL) 2mg and Nicotinamide 20mg
7 200 000 32% Portfolio Pharmaceuticals (Pty) Ltd
VWB81 Portfolio Vitamin B Co Strong tablets
R 1.6600 28 tablets 14 1000 98.45 180339611 CO
405 Warfarin 5mg tablet, 100 tablets
397 888 Pharmacare Limited V2205 Aspen Warfarin 5mg Tabs 100
R 68.3658 100 tablets 14 15 95.00 189759084 CO
406 Zinc tablet, scored, dispersible, equivalent to elemental zinc 20mg, 10 tabletsMCC registerd
214 808 Zinplex Marketing CC V22Z6 Zinplex Soluble Tablets
R 5.9600 10 tablets 14 100 units 90.00 181896936 CO
407 Zinc tablet, scored, dispersible, equivalent to elemental zinc 20mg, 100 tabletsMCC registerd
50 320 Zinplex Marketing CC V22Z6 Zinplex Soluble Tablets
R 9.9600 100 tablets 14 100 units 90.00 181862059 CO
Page 28 of 28
0
Special Requirements and Conditions of Contract
HP09–2016SD
THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH
FOR THE PERIOD 01 AUGUST 2016 TO 31 JULY 2018
VALIDITY PERIOD: 120 days
National Department of Health
Compulsory Briefing Session 09 February 2016 Time: 9:00–11:00
Venue: National Department of Health
Civitas Building, Impilo Board Room, North Tower, Podium Level
242 Struben Street (Cnr Thabo Sehume and Struben streets), Pretoria
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 1 of 3
INDEX SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT ............................................. 2
1. BACKGROUND .................................................................................................................... 2
2. EVALUATION CRITERIA: ................................................................................................... 2
2.1. PREFERENCE POINTS SYSTEM .................................................................................... 2
2.2. PREFERENCE FOR LOCAL MANUFACTURERS ......................................................... 3
3. PARTICIPATING AUTHORITIES ....................................................................................... 4
3.1. POST AWARD PARTICIPATION ....................................................................................... 4
4. CONTRACT PERIOD .......................................................................................................... 4
5. CENTRAL SUPPLIER DATABASE (CSD) ....................................................................... 5
6. DOCUMENT SUBMISSION AND COMPLETION FOR BIDDING ................................ 5
6.1. BID DOCUMENTS FOR SUBMISSION ............................................................................ 5
6.2. COMPLETION OF DOCUMENTS AND BID SUBMISSION .......................................... 6
7. TAX CLEARANCE CERTIFICATE ..................................................................................... 7
8. LEGISLATIVE REQUIREMENTS AND AUTHORISATION DECLARATION ............. 7
8.1. LEGISLATIVE REQUIREMENTS ...................................................................................... 7
8.2. DECLARATION OF AUTHORISATION ............................................................................ 8
9. BIDDING PROCESS ADMINISTRATION ......................................................................... 8
10. COUNTER CONDITIONS ................................................................................................... 9
11. PROHIBITION OF RESTRICTIVE PRACTICES ............................................................. 9
12. FRONTING .......................................................................................................................... 10
13. PRODUCT COMPLIANCE ................................................................................................ 10
13.1. SUBMISSION OF SAMPLES ........................................................................................... 10
14. PRODUCT AWARD ........................................................................................................... 11
14.1. AWARD CONDITIONS ...................................................................................................... 11
14.2. SPLIT AND MULTIPLE AWARDS ................................................................................... 11
14.3. PRE AWARD SUPPLIER DUE DILIGENCE .................................................................. 12
15. PRICE QUALIFICATION ................................................................................................... 12
16. PRICE REVIEW .................................................................................................................. 13
16.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS ..................... 13
16.2. INSTRUCTIONS FOR PRICE BREAKDOWN ............................................................... 13
16.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK ................... 14
APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS ................................................ 15
ROUTINE PRICE ADJUSTMENTS ................................................................................................. 15
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 2 of 3
EXCEPTIONAL PRICE ADJUSTMENTS ....................................................................................... 15
16.4. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW ............................... 16
17. ORDERS, DELIVERY AND CONTINUITY OF SUPPLY .............................................. 16
17.1. ORDERS .............................................................................................................................. 16
17.2. DELIVERIES ........................................................................................................................ 17
17.3. CONTINUITY OF SUPPLY ............................................................................................... 18
18. PACKAGING AND LABELLING ....................................................................................... 19
18.1. PACKAGING ....................................................................................................................... 19
18.2. LABELLING ......................................................................................................................... 20
18.3. BARCODES ......................................................................................................................... 20
19. QUALITY .............................................................................................................................. 21
20. SHELF-LIFE ........................................................................................................................ 21
21. POST AWARD .................................................................................................................... 21
21.1. MONITORING ..................................................................................................................... 21
21.2. REPORTING ....................................................................................................................... 22
21.3. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS ... 23
21.4. THIRD PARTIES ................................................................................................................. 23
21.5. CONTACT DETAILS .......................................................................................................... 23
22. ABBREVIATIONS ............................................................................................................... 24
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 2 of 24
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT
1. BACKGROUND
This bidding process, and all contracts emanating therefrom, will be subject to the
General Conditions of Contract issued in accordance with Treasury Regulation 16A
published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The
Special Requirements and Conditions of Contract are supplementary to the General
Conditions of Contract. Where the Special Requirements and Conditions of Contract
are in conflict with the General Conditions of Contract, the Special Requirements and
Conditions of Contract will prevail.
2. EVALUATION CRITERIA:
2.1. PREFERENCE POINTS SYSTEM
2.1.1. In terms of Regulation 6 of the Preferential Procurement Regulations, published in
terms of the Preferential Procurement Policy Framework Act, 2000 (Act 5 of 2000),
responsive bids will be adjudicated on the basis of the 90/10-preference point
system in terms of which points are awarded to bidders on the basis of:
The bid price (final delivered price including VAT): maximum 90 points
B-BBEE status level of bidder: maximum 10 points
2.1.2. The following formula will be used to calculate the points for price:
90 1
Where:
Ps= Points scored for comparative price of bid under consideration
Pt= Comparative price of bid under consideration
Pmin= Comparative price of lowest acceptable bid
2.1.3. A maximum of 10 points may be allocated to a bidder for attaining their B-BBEE
status in accordance with the table below:
B-BBEE Status Level of Contributor Number of Points
1 10 2 9 3 8 4 5 5 4 6 3
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 3 of 24
B-BBEE Status 7 2 8 1
Non-compliant contributor 0
2.1.4. Bidders are required to complete the preference claim form (SBD 6.1) irrespective of
whether B-BBEE status level points are claimed or not.
2.1.5. Only bidders who have completed and signed the declaration part of the preference
claim form, and who have submitted a B-BBEE status level certificate issued by a
registered auditor, accounting officer (as contemplated in section 60(4) of Close
Corporation Act, 1984 (Act 69 of 1984)) or an accredited verification agency will be
considered for preference points.
2.1.6. Bidders that fail to comply with paragraphs 2.1.4 and 2.1.5 will be allocated zero
points for B-BBEE status.
2.1.7. The points scored by a bidder for B-BBEE contribution will be added to the points
scored for price.
2.1.8. The points scored will be rounded off to the nearest 2 decimal points.
2.1.9. The National Department of Health may, before a bid is adjudicated or at any time,
require a bidder to substantiate claims it has made with regard to preference points.
2.1.10. In the event that two or more bids have scored an equal number of total points, the
contract will be awarded to the bidder scoring the highest number of points for B-
BBEE. Should two or more bids be equal in all respects, the award shall be decided
by the drawing of lots.
2.1.11. A contract may, on reasonable and justifiable grounds, be awarded to a bid that did
not score the highest number of points.
2.2. PREFERENCE FOR LOCAL MANUFACTURERS
2.2.1. The Department may give preference to pharmaceutical manufacturers who
formulate and/or package products in South Africa as specified by the Department of
Trade and Industry. This list of specified products may be published on the National
Department of Health website, www.health.gov.za.
2.2.2. In the event that a list of designated items is published, these may be awarded to
local pharmaceutical manufacturers, provided such an award does not impact upon
security of supply and/or affordability.
2.2.3. Bids for products that qualify for preference, must comply with all of the following
criteria:
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 4 of 24
The site/s of manufacture and/or packaging for the product offered is located in
South Africa;
The Medicine Registration Certificate, issued by the Medicines Control Council,
or its successor in title, in terms of the Medicines and Related Substances Act,
Act 101 of 1965, as amended, includes the proposed South African
manufacturer and/or packer site/s;
Where there are alternative offers, the reference price as published by National
Department of Health has not been exceeded;
Bids are within 10% of the highest points scored for the item;
Previous supplier performance;
Compliance to all other provisions contained in these Special Requirements and
Conditions of Contract.
3. PARTICIPATING AUTHORITIES The National Department of Health and the following Provincial Departments of
Health will participate in this contract: Eastern Cape, Free State, Gauteng,
KwaZulu-Natal, Limpopo, Mpumalanga, Northern Cape, North West and Western
Cape.
3.1. POST AWARD PARTICIPATION
Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities,
Constitutional Entities and Public Entities, issued in terms of the Public Finance
Management Act, 1999, (Act 1 of 1999), states that the Accounting
Officer/Accounting Authority may, on behalf of a department, constitutional
institution or public entity, request to participate in any contract arranged by means
of a competitive bidding process by any organ of state, subject to the written
approval of such organ of state and the relevant contractors. The Participating
Authorities on this contract may therefore be extended in terms of this Regulation.
4. CONTRACT PERIOD
The contract period shall commence on 01 August 2016 and expire on 31 July
2018.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 5 of 24
5. CENTRAL SUPPLIER DATABASE (CSD)
5.1. The Central Supplier Database (CSD) is managed by National Treasury to serve as
the source of all supplier information for all spheres of government. The purpose of
centralising government’s supplier database is to reduce duplication of effort and
cost for both supplier and government while enabling electronic procurement
processes.
5.2. It is a compulsory requirement that all bidders be registered on the CSD at the
closing time of the bid (date and hour specified in the bidding documents).
Furthermore, suppliers must provide the unique supplier number and security code
allocated to them as part of the bid document.
5.3. The bid will be deemed non-responsive if the bidder fails to provide the unique
supplier number and security code.
5.4. For information regarding registration on the CSD, go to www.csd.gov.za.
6. DOCUMENT SUBMISSION AND COMPLETION FOR BIDDING
6.1. BID DOCUMENTS FOR SUBMISSION
6.1.1. Bidders MUST submit the following completed and signed documents in the Bid
Pack:
SBD1: Invitation to bid
SBD4: Declaration of Interest
SBD5: The National Industrial Participation Programme
SBD6.1: Preference points claim form in terms of the Preferential Procurement
Regulations 2011
SBD8: Declaration of bidder's past supply chain management practices
SBD9: Certificate of independent bid determination
PBD1: Authorisation Declaration (if applicable)
PBD4.1: Supplier details
PBD5: Declaration of Compliance with Good Manufacturing Practice (GMP)
PBD7: Compulsory briefing session attendance certificate
Bid Response Document: Completion of all response fields per item offered is
mandatory.
B-BBEE Status Level Verification Certificate (where preference points are
claimed) (Original or Certified Copy)
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 6 of 24
A certified copy of the license to manufacture, including all annexures, issued by
the Medicines Control Council, or its successor in title, in terms of the Medicines
and Related Substances Act, Act 101 of 1965, as amended.
Certified copy of the Medicine Registration Certificate (GW12/7) with all the
associated conditions, issued by the Medicines Control Council, or its successor
in title, in terms of the Medicines and Related Substances Act, Act 101 of 1965,
as amended.
Copy of the package insert approved by the Medicines Control Council, or its
successor in title, for each product offered. Each package insert must be in A4
format.
6.2. COMPLETION OF DOCUMENTS AND BID SUBMISSION
6.2.1. Bidders are required to submit three sets of bid documents according to the
instructions below.
6.2.2. Set 1: Hard copy (constitutes the legally binding bid document)
All SBD, PBD and Bid Response forms must be typewritten in black ink. Where no
electronic entry field is provided bidders must complete the forms in black ink,
handwritten in capital letters. The signed hard copy of the bid document will serve
as the legal bid document. Bidders must submit their complete bid in hard copy
format (paper document).
The Chief Executive Officer, Chief Financial Officer, or authorised designee of the
entity submitting the bid must attach his/her official signature where indicated on
the documents. All pages in the bid submission must be initialled by the same
person with black ink. The use of correction fluid is not acceptable. Any change/s
must be clearly indicated and initialled.
6.2.3. Set 2: Scanned version of Set 1. (i.e. Scanned complete hard copy)
Bidders must submit a PDF version of the entire signed hardcopy bid, including all
certificates and documents requested.
6.2.4. Set 3: Electronic version of bid documents
Bidders must submit the electronic versions of all bidding documents to facilitate
data extraction. The PDF document must be submitted as editable PDF and the
Bid Response Document in Excel (not PDF).
6.2.5. Set 2 and Set 3 must be included on a CD and submitted in a sealed package with
Set 1. The full name and address of the bidder, including the return address of the
bidder, the bid number and the closing date of the bid must be clearly indicated on
the package. All fields must be completed. Where information requested is not
relevant this should be indicated with N/A.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 7 of 24
6.2.6. All three sets must be submitted before the closing time of the bid (date and hour
specified in the bidding documents).
6.2.7. All three sets of information must be submitted in order for the bid to be deemed
complete. Incomplete bids will be deemed non-responsive.
7. TAX CLEARANCE CERTIFICATE
Bidders will not be required to provide an original valid tax clearance certificate to
departments as part of the documents for this bid. In any circumstances where the
CSD encounters challenges, the Department reserves the right to request the
provision of a valid tax clearance certificate which must be provided within ten days
of request.
8. LEGISLATIVE REQUIREMENTS AND AUTHORISATION
DECLARATION
8.1. LEGISLATIVE REQUIREMENTS
8.1.1. All medicines offered by bidders must be registered in terms of section 15 of the
Medicines and Related Substances Act, Act 101 of 1965, as amended. The
medicines must comply with the conditions of registration for the duration of the
contract.
8.1.2. For all offered products, the bidder must be indicated as the applicant on the
Medicine Registration Certificate GW12/7, issued in terms of section 15(3)(a) of
the Medicines and Related Substances Act, Act 101 of 1965, as amended.
8.1.3. In exceptional circumstances the National Department of Health may accept bids
from bidders who are not indicated as the applicant on the Medicine Registration
Certificate. The decision to consider such bids will be made on a case-by-case
basis.
8.1.4. In the event of a bidder not being the applicant, all details of the agreement
between the bidder and the applicant must be disclosed as per paragraph 9.2 of
the Special Requirements and Conditions of Contract and the Authorisation
Declaration (PBD1) forms submitted.
8.1.5. The bidder offering a product must be the holder of a licence to manufacture
medicines in terms of section 22C(1)(b) of the Medicines and Related Substances
Act, Act 101 of 1965, as amended.
8.1.6. Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of
1978) and the Trade Marks Act, 1993 (Act 194 of 1993) as amended. Where
applicable, an explanation for non-compliance must be provided.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 8 of 24
8.2. DECLARATION OF AUTHORISATION
8.2.1. Only the holder of a certificate of registration in terms of the Medicines and Related
Substances Act, Act 101 of 1965, as amended may submit a bid.
8.2.2. In the event that the Manufacturer, Packer or other, as listed on the medicine
registration certificate, are external, third parties the bidder must ensure that all
legal, financial and supply arrangements have been mutually agreed upon
between the bidder and these third parties.
8.2.3. Where third parties are involved the bidder must submit a duly completed and
signed Authorisation Declaration (PBD1). Failure to submit the full declaration will
invalidate the bid for such goods offered.
8.2.4. The National Department of Health reserves the right to verify any information
supplied by the bidder in the Authorisation Declaration at any time. Should the
information be found to be false or incorrect, the National Department of Health will
exercise any of the remedies available to it in order to disqualify the bid, or cancel
the contract, if already awarded.
8.2.5. No agreement between the bidder and a third party will be binding on the National
Department of Health or Participating Authorities.
8.2.6. Accountability with regard to meeting the conditions of any contract emanating
from this bidding process rests with the successful bidder and not any third party.
9. BIDDING PROCESS ADMINISTRATION
9.1. All communication between the bidder and the National Department of Health must
be in writing and addressed to the Director: Affordable Medicines.
9.2. The Affordable Medicines Directorate within the National Department of Health is
responsible for managing the bidding process and will communicate with bidders to
request extension of the validity period of the bid, should it be necessary.
9.3. Any unsolicited communication between the closing date and the award of the
contract between the bidder and any government official or a person acting in an
advisory capacity for the National Department of Health in respect to any bids, is
discouraged.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 9 of 24
10. COUNTER CONDITIONS
Any amendments to any of the bid conditions, changes to bid specifications or
setting of any other counter conditions by bidders will result in the invalidation of
such bids.
11. PROHIBITION OF RESTRICTIVE PRACTICES
11.1. In terms of section 4(1) of the Competition Act, Act 89 of 1998, as amended, an
agreement between, or concerted practice by, firms, or a decision by an association
of firms, is prohibited if it is between parties in a horizontal relationship and if a
bidder(s) is/are or a contractor(s) was/were involved in:
directly or indirectly fixing a purchase or selling price or any other trading
condition;
dividing markets by allocating customers, suppliers, territories or specific types
of goods or services; or
collusive bidding.
11.2. Section 4(2) of Act 89 of 1998 states that an agreement to engage in a restrictive
horizontal practice referred to in subsection (1)(b) of the Act is presumed to exist
between two or more firms if:
any one of those firms owns a significant interest in the other, or they have at
least one director or substantial shareholder in common; or
any combination of those firms engages in that restrictive horizontal practice.
11.3. If a bidder or contracted supplier, in the judgement of the purchaser, has engaged in
any of the restrictive practices referred to above, the purchaser may refer the matter
to the Competition Commission for investigation and possible imposition of
administrative penalties as contemplated in the Competition Act 89 of 1998.
11.4. If a bidder or contracted supplier has been found guilty by the Competition
Commission of any of the restrictive practices referred to above, the purchaser may,
in addition and without prejudice to any other remedy provided for, invalidate the bid
for such item(s) offered, and/or terminate the contract in whole or part, and/or
restrict the bidder or contracted supplier from conducting business with the public
sector for a period not exceeding ten (10) years and/or claim damages from the
bidder or contracted supplier concerned.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 10 of 24
12. FRONTING
12.1. The Department of Health supports the spirit of broad-based black economic
empowerment and recognises that real empowerment can only be achieved through
individuals and businesses conducting themselves in accordance with the
Constitution and in an honest, fair, equitable, transparent and legally compliant
manner. Against this background the Department of Health condemns any form of
fronting.
12.2. The National Department of Health may, as part of the bid evaluation processes,
conduct or initiate the necessary enquiries/investigations to determine the accuracy
of the representation made in bid documents. Should any of the fronting indicators
as contained in the Guidelines on Complex Structures and Transactions and
Fronting, issued by the Department of Trade and Industry, be established during
such enquiry/investigation, the onus will be on the bidder/contractor to prove that
fronting does not exist. Failure to do so within a period of 14 days from date of
notification may invalidate the bid/contract and may also result in the restriction of the
bidder/contractor to conduct business with the public sector for a period not exceeding
ten years, in addition to any other remedies the National Treasury may have against
the bidder/contractor concerned.
13. PRODUCT COMPLIANCE
Prior to award products will be evaluated for:
Compliance with specifications as set out in the Bid Response Document.
Registration of product in terms of the Medicines and Related Substances Act,
Act 101 of 1965, as amended.
Availability of samples at both sample evaluation sites as detailed in paragraph
13.1.
13.1. SUBMISSION OF SAMPLES
13.1.1. Samples must be submitted to each of the addresses indicated below, prior to
closing date and time of bid:
Mr Dumisani Malele Mr Nisaar Mia Depot Manager Pharmaceutical Policy Specialist Tel: 011 628 9001 Tel: 021 483 5800 Gauteng: Medical Supplies Depot Western Cape: Department of Health Transito In Pharmaceutical Services 35 Plunkett Avenue 4 Dorp Street Room 10-07 Hurst Hill Cape Town 2092 8001
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 11 of 24
13.1.2. No samples must be sent to the Directorate: Affordable Medicines at the National
Department of Health.
13.1.3. Samples must be marked with the bid number, the item number as well as the
bidder’s name and address.
13.1.4. Bidders must submit at least one original pack of each offer for evaluation.
13.1.5. Bids where samples are not submitted to both facilities listed in paragraph 13.1.1,
will not be considered for award.
13.1.6. It is the responsibility of the bidder to ensure that samples have been received at
the addresses provided.
13.1.7. All samples for awarded items will be retained for the period of the contract.
13.1.8. All samples must be a true representation of the product which will be supplied.
13.1.9. All samples submitted must be inclusive of the MCC approved package insert.
13.1.10. In the case of schedule 6 items, only an empty original package and the MCC
approved package insert must be submitted and NOT the content of the package.
14. PRODUCT AWARD
14.1. AWARD CONDITIONS
14.1.1. The National Department of Health reserves the right not to award a line item.
14.1.2. The National Department of Health reserves the right to negotiate prices.
14.1.3. In cases where the tender does not achieve the most economically advantageous
price, the National Department of Health reserves the right not to award that item.
14.1.4. Pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day
pack size be offered, no conversion factor will be applied. Direct comparisons will
be made between 28 and 30-day pack sizes during evaluation.
14.1.5. The Department of Health may change treatment protocols and/or product
formulations where required, due to emerging clinical evidence, disease profiles,
safety or resistance patterns. In these circumstances, the National Department of
Health reserves the right to cancel the contract for an item or a vary the quantity
awarded based on expected changes in projected demand. In these instances, the
Department of Health will notify the contracted supplier within a reasonable time of
the expected change. However, in cases where patient safety is a concern, these
changes may be implemented with immediate effect.
14.2. SPLIT AND MULTIPLE AWARDS
14.2.1. The National Department of Health reserves the right to issue split or multiple
awards, where necessary, to ensure security of supply.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 12 of 24
14.2.2. The following will be taken into consideration when contemplating a split award:
Source of API and manufacturing site.
Capacity to meet expected demand as per published estimates in the Bid
Response Document.
Estimated volume to be supplied.
Risk to public health if the item is not available.
Past compliance of the bidder with contractual obligations.
14.2.3. Two-way split awards will be made in accordance with the following schedule
based on the points scored:
Category Difference between points
scored
Recommended percentage
split
A Equal points 50/50
B < 5 points 60/40
C >5-10 points 70/30
D >10-20 points 80/20
E >20 points 90/10
14.2.4. Where a split for more than 2 suppliers is contemplated, the following formula will
used to allocate volumes for award:
For a three way split: Supplier share = 33.3% + (supplier score - mean score) x
2.3%
For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%
14.3. PRE AWARD SUPPLIER DUE DILIGENCE
The National Department of Health reserves the right to conduct supplier due
diligence prior to the final award of contract. Supplier capacity may be assessed
based on past compliance of the bidder with contractual obligations and
manufacturing capacity as declared by the bidder.
15. PRICE QUALIFICATION
15.1. Bidders must quote a final price inclusive of delivery and Value Added Tax (VAT).
15.2. If a price exclusive of VAT is submitted the bid will be deemed non-responsive.
15.3. The bid price offered for a product is deemed to be for the pack size as advertised
in the item specification.
15.4. Prices submitted must not exceed the Reference Price as published.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 13 of 24
15.5. Prices submitted must not exceed the ex manufacturer component of the Single
Exit Price.
15.6. Prices submitted for this bid will be regarded as firm and subject only to review in
terms of Paragraph 16.
15.7. Bidders are advised to refer to the Reference Price List for HP09-2016SD
published on the National Department of Health website (www.health.gov.za)
before preparing the bid submission.
16. PRICE REVIEW
The National Department of Health envisages three types of price review processes
for the duration of this contract:
A routine adjustment to mitigate foreign exchange fluctuations;
An exceptional adjustment to mitigate significant short-term foreign exchange
fluctuations; and
A systematic review of prices for comparable products available in the
international market place.
16.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS
16.1.1. Eligibility for price adjustments relating to foreign exchange risk depends on:
The submission of a complete price breakdown per instructions below for all
relevant products; and
Assessment of the rationality of this price breakdown by the National
Department of Health.
16.2. INSTRUCTIONS FOR PRICE BREAKDOWN
16.2.1. The price breakdown must be completed on the signed bid response document as
well as the electronic version. The delivered price must be divided across five
components:
1. Active Pharmaceutical Ingredients (API); 2. Formulation; 3. Packaging; 4. Logistics; 5. Gross margin (remaining portion).
16.2.2. The sum of these categories must be equal to 100% of the delivered price for the
line item.
16.2.3. The local + imported portions of the first three components must add up to 100%
within each component (e.g. Portion of API attributable to local + Portion of API
attributable to import = 100% of specific API component).
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 14 of 24
16.2.4. VAT must be apportioned equally across all components and not regarded as a
separate component.
16.2.5. Labour must be apportioned appropriately across the relevant components.
16.2.6. Breakdown must be in percentage format to the closest whole percentage (e.g.
20%).
16.2.7. The National Department of Health reserves the right to engage with bidders to
verify any of the components of the bid price, which may include audit of invoices
and related documentation.
16.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK
16.3.1. Only the portion of the bid price facing foreign exchange risk will be adjusted. This
portion is determined by the price breakdown on the signed bid submission.
16.3.2. Adjustments are always calculated using the original awarded contracted price as
the base.
16.3.3. Price adjustments relating to foreign exchange will be based on the percentage
change between the relevant base average rate of exchange (RoE) and an
adjustment average RoE. Rates are sourced from the Reserve Bank
(www.resbank.co.za).
16.3.4. Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of
evidence of poor compliance with contractual obligations.
16.3.5. Base average RoE for this tender will be as follows, per currency:
Currency Base Average Rates of Exchange for the period 01 August 2015 to
28 January 2016 Rand per US Dollar R 14.2193 Rand per Br Pound R 21.5151
Rand per Euro R 15.6583
Yuan Renminbi per Rand CN¥ 0.4530
Indian Rupee per Rand I ₹ 4.6702
16.3.6. Should the bidder make use of any currency not mentioned above, the bidder must
stipulate this clearly and submit the calculated average RoE for the period 01
August 2015 to 28 January 2016 using the South African Reserve Bank published
rates for the specific currency.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 15 of 24
APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS
16.3.7. Scanned copies of signed applications for price adjustments must be received by
the National Department of Health prior to the submission dates detailed in the
tables below.
16.3.8. Where no application for an adjustment relating to foreign exchange has been
received and such an adjustment would be favourable to the Department, this will
be implemented automatically.
16.3.9. Foreign exchange adjustments may never result in a price exceeding the current
Single Exit Price, ex Logistics.
ROUTINE PRICE ADJUSTMENTS
16.3.10. Schedules for routine price reviews, and periods for calculating adjustment
average RoE, are detailed in the table below:
Review Period for calculating adjustment average RoE
Submission of request for price review to reach the
office by
Date from which adjusted prices will become
effective 1 1 July2016 –
31 December 2016 03 January 2017 1 February 2017
2 1 January 2017 – 30 June 2017
03 July 2017 1 August 2017
3 1 July 2017 – 31 December 2017
03 January 2018 1 February 2018
EXCEPTIONAL PRICE ADJUSTMENTS
16.3.11. Suppliers may request exceptional price adjustments according to the schedule in
the table below. These will be activated if the absolute change between the base
RoE and the three month retrospective average RoE indicated in the table below
fluctuates by more than 10%.
Review Period for calculating adjustment average RoE
Submission of request for price review to reach the
office by
Date from which adjusted prices will become
effective 0.1 01 July 2016 –
30 September 2016 03 October 2016 01 November 2016
1.1 1 January 2017 – 31 March 2017
03 April 2017 01 May 2017
2.1 01 July 2017 – 30 September 2017
03 October 2017 01 November 2017
3.1 01 January 2018 – 31 March 2018
03 April 2018 01 May 2018
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 16 of 24
16.3.12. Suppliers who received exceptional adjustments will receive routine adjustments
based on the preceding three months, rather than the usual six month historical
average exchange rate. The periods for calculating adjustment average RoE in
these instances are detailed in the table below:
Review Period for calculating adjustment average RoE
post exceptional adjustment
Submission of request for price review to reach the
office by
Date from which adjusted prices will become
effective
1 1 October 2016 – 31 December 2016
03 January 2017 1 February 2017
2 1 April 2016 – 30 June 2017
03 July 2017 1 August 2017
3 1 October 2017 – 31 December 2017
03 January 2018 1 February 2018
16.4. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW
16.4.1. The National Department of Health reserves the right to review international prices
to identify lowest comparable global prices.
16.4.2. Where this review identifies any prices that are lower than contract prices the
National Department of Health will enter into price negotiations with the contracted
supplier.
16.4.3. Where the outcome of this negotiation is deemed unfavourable, the National
Department of Health reserves the right to terminate the award for the item in
question.
17. ORDERS, DELIVERY AND CONTINUITY OF SUPPLY
17.1. ORDERS
17.1.1. The quantities reflected in the advertised bid response document are estimated
volumes and are not guaranteed.
17.1.2. Fluctuations in monthly demand may occur.
17.1.3. Successful bidders will be informed of estimates specific to Participating
Authorities upon award.
17.1.4. Contracted suppliers and Participating Authorities are responsible for reviewing
these estimated quantities on a monthly basis in order to determine and commit to
a rolling quarterly demand plan, thus improving predictability of demand.
17.1.5. Proposed minimum order quantities should facilitate delivery directly to facilities.
The National Department reserves the right to negotiate minimum order quantities
where necessary. Where consensus regarding minimum order quantities cannot be
reached the bid may not be awarded.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 17 of 24
17.1.6. In order to facilitate efficient implementation of the direct delivery strategy
contracted suppliers must pack orders by facility as per the purchase order.
17.1.7. Only orders made using an official, authorised purchase order format are valid.
17.1.8. Suppliers are required to acknowledge receipt of all purchase orders received from
participating authorities, in a manner stipulated by the relevant participating
authority.
17.1.9. Changes to any quantities ordered may only be made upon receipt of an amended
purchase order.
17.1.10. The Participating Authorities reserve the right to cancel orders where the lead time
exceeds the delivery lead time specified in the contract (as per paragraph 17.2 of
the Special Requirements and Conditions of Contract) and may at their discretion
purchase supplies of a similar quality and up to the same quantity in substitution of
the goods not supplied in conformity with the contract (as per paragraph 21.6 of
the General Conditions of Contract).
17.1.11. In cases where an order is received which appears to be irrational or misaligned
with estimates, the contracted supplier must liaise with the relevant Participating
Authority prior to processing the order.
17.2. DELIVERIES
17.2.1. The initial lead time as proposed in the bid response document will be calculated
from date of award of the contract and NOT the date of placement of the first order.
This period may not exceed 75 calendar days from the date of award.
17.2.2. Lead-time within the contract period is defined as the time from submission of
order to supplier to time of receipt by the Department as confirmed by the Proof of
Delivery document. This lead-time may not exceed 14 calendar days.
17.2.3. Failure to comply with the contractual lead-time will result in penalties being
enforced as per paragraph 21 and 22 of the General Conditions of Contract.
17.2.4. Products and related documentation must be delivered in accordance with the
terms, conditions and delivery instructions stipulated on the purchase order.
17.2.5. The information on invoices and documents relating to delivery must comply with
the minimum data requirements as defined by the National Department of Health.
17.2.6. Invoices must reflect both the registered product name of the item and the item
description as it appears in the contract circular and Master Procurement
Catalogue (MPC).
17.2.7. Original invoices and proof of delivery must be authorised by a delegated official at
the designated delivery point. These documents must be delivered to the authority
responsible for payment. This may or may not be the same as the delivery address
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 18 of 24
stipulated on the purchase order. Suppliers are required to know where documents
must be delivered.
17.2.8. The supplier must ensure that products are delivered in accordance with the
appropriate conditions of storage, as per product's conditions of registration.
Delivery is deemed to terminate upon signature of receipt by the delegated official
as contemplated in paragraph 17.2.7
17.2.9. Discrepancies between invoice and physical stock, or damaged stock, will be
reported to the contracted supplier within a reasonable time or as arranged with
the supplier. This time period must make provision for the quantities received to be
checked upon receipt of delivery.
17.2.10. Contracted suppliers will be responsible for collection of goods delivered
erroneously, or in the incorrect condition as formally arranged in consultation with
the facility. The Participating Authorities may recoup any expenses associated with
failure to collect such goods in accordance with the agreement.
17.3. CONTINUITY OF SUPPLY
17.3.1. Contracted suppliers must:
have at least two months supply of the estimate at the start of the contract,
maintain sufficient stock to meet demand throughout the duration of the
contract;
inform the National Department of Health at first knowledge of any
circumstances that may result in interrupted supply, including but not limited to:
1. regulatory action which may impact on their GMP status or that of entities
on which they are reliant;
2. any anticipated problems associated with the availability of active
pharmaceutical ingredient (API);
3. industrial action;
4. challenges with manufacturing pipeline;
5. any other supply challenges.
direct official communication relating to continuity of supply to
[email protected], as well as Participating Authorities;
direct official communication relating to payment challenges to
[email protected], as well as Participating Authorities.
This official communication must include detail of corrective actions taken by the
contracted supplier to ensure continuity of supply.
17.3.2. It is the responsibility of the contracted supplier to ensure continuous availability
and supply of contracted items. In the event that the contracted supplier is unable
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 19 of 24
to supply in terms of 17.3.1 above, the contracted supplier will source alternative
product of acceptable quality and up to the same quantity as required in terms of
the contract. The substitute item will be supplied at the current price of the
contracted item.
17.3.3. Suppliers using the mechanism stipulated in 17.3.2 above may also be required to
pay penalties for supply exceeding the contractual lead time as stipulated in the
General Conditions of Contract Paragraph 22.
17.3.4. In terms of the General Conditions of Contract and Special Requirements and
Conditions of Contract, the Participating Authorities may purchase outside the
contract in order to meet its requirements if the item(s) are urgently required and
not immediately available.
18. PACKAGING AND LABELLING
18.1. PACKAGING
18.1.1. Suppliers must ensure that products delivered are received in good order at the
point of delivery. Packaging must be suitable for further dispatch, storage and
stacking according to Good Wholesaling Practice and Good Distribution Practice.
18.1.2. Packaging must be suitable for transportation and should prevent exposure to
conditions that could adversely affect the stability and integrity of the product.
18.1.3. The packing must be uniform for the duration of the contract period. All products
must be packed in acceptable containers, specifically developed for the product.
18.1.4. The number of units in the unit pack, shelf pack and shipper pack must be
completed in the Bid Response Document.
18.1.5. Where a particular stacking and storage configuration is recommended by the
supplier, this should be clearly illustrated on the outer packaging.
18.1.6. Where the contents of the shipper pack represents a standard supply quantity of
an item, the following must be adhered to:
Outer packaging flanges must be sealed with suitable tape that will clearly
display evidence of tampering.
The contents must be packed in neat, uniform rows and columns that will
facilitate easy counting when opened.
18.1.7. Where the contents of a shipper pack represents a non-standard supply quantity,
the following must be adhered to:
Outer packaging flanges must be sealed with suitable tape that will clearly
display evidence of tampering.
The shipper pack must contain only one product, mixing of multiple items in a
single shipper is not allowed.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 20 of 24
The outer packaging must be clearly marked as a "Part Box".
18.2. LABELLING
18.2.1. All containers, packaging and cartons must be clearly labelled. Bulk packs must be
labelled in letters not less than font size 48.
The following information must be clearly and indelibly printed on all shelf and
shipper packs, including any part boxes:
Item name as contained in the contract circular and the Master Procurement
Catalogue (MPC);
Registered product name (if applicable);
Number of units in pack (e.g. for bulk packs 80 x 10 x 100s);
Batch number;
Expiry date;
Storage conditions;
Barcode.
18.2.2. Where the contents of the shipper requires special attention in terms of storage
and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such
instructions must be clearly and visibly indicated on the outer packaging on a
brightly coloured background.
18.2.3. Unit packs must be labelled in accordance with Regulation 8 of the General
Regulations published in terms of the Medicines and Related Substances Act, Act
101 of 1965, as amended. The label must include a barcode.
18.3. BARCODES
18.3.1. It is mandatory that all products supplied must include a barcode (number plus
symbology). All shipper, shelf and unit packs must be marked with the appropriate
number and symbology. The European Article Numbering Code 13 (EAN 13) has
been accepted as standard.
18.3.2. Suppliers are encouraged to include a 2D barcode or similar on their packaging
that will include the following information:
Item name as contained in the contract circular and the Master Procurement
Catalogue (MPC);
Registered product name (if applicable);
Dosage form and strength;
Pack size;
Batch number;
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 21 of 24
Expiry date.
19. QUALITY
Products must conform with the conditions of registration of the product with Medicines
Control Council for the full duration of this contract.
20. SHELF-LIFE
20.1. Unless the stability of a product has required the MCC to approve a shorter shelf life,
products must have a shelf-life of at least 18 months upon delivery.
20.2. Contracted suppliers may apply in writing to Participating Authorities to supply a
product with a shorter shelf life provided that:
Applications are accompanied by an undertaking that such short-dated
products will be unconditionally replaced or credited before or after expiry; and
applications are approved before execution of orders; and
such products must be collected by the supplier at their own cost; and
failure to collect the products within 30 days after written notification to the
supplier will result in the disposal of the product by the Participating Authority
for the account of the supplier.
20.3. If short-dated products are delivered without the aforementioned undertaking the
following discount formula will be applied for invoicing of short-dated products:
A = (18 – months to date of expiry) x 2% x consignment value short dated product.
Therefore, amount to be invoiced is: Consignment value minus A, where A is the
value of the outcome of the discount formula.
20.4. Unless otherwise agreed to in terms of 20.2, any Participating Authority may, without
prejudice, decline to accept product with a shelf-life of less than 18 months.
21. POST AWARD
21.1. MONITORING
21.1.1. The management of the contract is the responsibility of the National Department of
Health. All correspondence in this regard must be directed to the Director: Affordable
Medicines.
21.1.2. Contracted suppliers must advise the Director: Affordable Medicines at first
knowledge of any unforeseeable circumstances that may adversely affect supply
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 22 of 24
against the contract. Full particulars of such circumstances must be provided by the
supplier as contemplated in paragraph 17.3.
21.1.3. The National Department of Health, in collaboration with the other Participating
Authorities, will monitor the performance of contracted suppliers and maintain a
scorecard for compliance to the terms of this contract as follows:
Compliance with delivery lead times;
Percentage of orders supplied in full first time;
Compliance with reporting requirements according to reporting schedule and
reporting mechanism. As a minimum suppliers will be required to submit the
following information in a specified format and via a mechanism defined by the
National Department of Health:
All transactional data relating to orders;
A monthly age analysis;
Pipeline data;
Status of outstanding orders.
Attendance of compulsory quarterly meetings: The National Department of
Health will hold quarterly meetings with suppliers to review the next quarter's
demand, as well as supplier performance.
21.1.4. The National Department of Health will request Participating Authorities to impose
penalties, where deemed necessary, as per Paragraph 21 and 22 of the General
Conditions of Contract.
21.1.5. Non-compliance of contracted suppliers in terms of this contract may influence
participation in future contracts .
21.2. REPORTING
21.2.1. National Department of Health will provide an indication of reporting requirements
at the compulsory briefing session and successful bidders will be assisted with
adopting these requirements.
21.2.2. The National Department of Health may, from time to time and within reason, add
to the reporting requirements. Any changes to reporting requirements or the
reporting mechanism will be communicated in writing by the Director: Affordable
Medicines.
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 23 of 24
21.3. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER
DETAILS
21.3.1. Where a contracted supplier plans to merge with or is going to be acquired by
another entity, or plans to cede a contract the contracted supplier must inform the
National Department of Health in writing at first knowledge of such an event.
21.3.2. The National Department of Health reserves the right to agree to the transfer of
contractual obligations to the new supplier under the prevailing conditions of contract
or to cancel the contract.
21.3.3. A contracted supplier must inform the National Department of Health at first
knowledge of any changes to address, name, or contact details.
21.4. THIRD PARTIES
21.4.1. Participating Authorities will not make a payment to or consult with a third party.
21.4.2. No third party is entitled to put an account of a Participating Authority on hold.
21.5. CONTACT DETAILS
Postal address Director: Affordable Medicines, Private Bag X828, Pretoria, 0001
Physical address Director: Affordable Medicines, Civitas Building, 242 Struben Street, Cnr Thabo Sehume Street, Pretoria, 0001
Please use the following e-mail address and contact persons for any queries
relating to bidding process:
Ms B May Ms M Rasengane
Tel: (012) 395 8442 Tel: (012) 395 9452
Fax number: (012) 395 8823
Email: [email protected]
SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD
Page | 24 of 24
22. ABBREVIATIONS
The abbreviations used in this document signify the following:
API Active Pharmaceutical Ingredient
B-BBEE Broad-Based Black Economic Empowerment
BEC Bid Evaluation Committee
CD Compact Disc
CSD Central Supplier Database
EAN European Article Number
GMP Good Manufacturing Practice
MCC Medicines Control Council
MPC Master Procurement Catalogue
NDoH National Department of Health
PDF Portable Document Format
RoE Rate of Exchange
SARS South African Revenue Service
VAT Value Added Tax